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ABSTRACT
Although melanoma is largely curable when detected in its earliest stages, it can
metastasise to other tissues, drastically reducing survival rates. The most recent
therapies used to treat metastatic melanoma are effective long-term in only 11 to 33% of
patients. Our ability to monitor treatment failure is limited. New prognostic markers are
urgently required to allow monitoring of treatment response and disease progression.
Circulating tumour cells (CTCs) are released into the bloodstream by the tumours within
a patient, this being a key step in melanoma spread. Since CTCs can be detected in the
blood of metastatic melanoma patients, these cells can be used as a “liquid biopsy”,
providing critical insight into each person’s melanoma biology.
Melanoma CTCs have been described as very heterogeneous, hindering their isolation via
commonly used CTC capturing methods. To address this, microfluidic devices have been
developed to isolate viable CTCs from blood, independently of their marker expression.
This study aimed to determine the effectiveness of two different microfluidic devices
(Slanted and A5) in recovering melanoma cell lines, and their potential use in the isolation
of CTCs from the blood of metastatic melanoma patients. It also aimed to study additional
cancer or melanoma specific markers to be used in immunostaining protocols for
detection of CTCs after microfluidic enrichment.
The optimal isolation procedure was identified as two rounds of enrichment with the
Slanted spiral device, after which we obtained a 3-log depletion of white blood cells and
a recovery of over 60% when cells from two melanoma cell lines were spiked into blood
samples from healthy volunteers. In addition, we optimised the detection of CTCs using
four melanoma markers (gp100, Melan-A, s100 and MCSP) combined in a multimarker
immunocytochemistry staining protocol. The optimised enrichment and detection
procedures were validated in a cohort of ten metastatic melanoma patients. Results
showed that 40% of the patients had one or more CTCs in their blood (1-4 CTCs/8 mL of
blood).
Furthermore, three additional markers (Vimentin, RANK, and ABCB5) were trialled so as
to increase detection of highly heterogeneous melanoma CTCs in samples that have been
processed through the Slanted microfluidic device.
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The improved enrichment and detection of CTCs in the blood of melanoma patients using
the methods developed as part of this study will facilitate the molecular, genomic and
functional characterisation of melanoma CTCs. This will ultimately improve our
understanding of the biology of melanoma CTCs and their role in metastatic spread and
treatment response.
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1. INTRODUCTION

1. INTRODUCTION
Melanoma is an aggressive cutaneous cancer responsible for the majority of skin cancerrelated deaths and its incidence is increasing worldwide1. Generally, patients are
considered cured after complete surgical resection of the primary tumour. Nevertheless,
around 20% of patients will develop metastatic disease, which is extremely difficult to
treat2.
The use of targeted therapies and immunotherapies has improved the survival of these
patients, but the prognosis is still poor due to the development of drug resistance to
targeted therapies and low response rates to immunotherapies. Moreover, adverse sideeffects of current immunotherapies restrict treatment efficacy in some cases3. Therefore,
new biomarkers are urgently needed to allow personalised monitoring of the disease,
with the aim to determine treatment response and recurrence at earlier stages. This will
allow optimal selection of therapy that improves survival rates in patients.
Circulating tumour cells (CTCs) appear in the peripheral blood from primary or
metastatic solid tumours as the first step in tumour metastasis. Cancer cells enter the
bloodstream and travel to distant organs where they may initiate development of a new
tumour.
During the last decade, the quantification of CTCs has been described in the literature, as
a prognostic marker in various tumours such as breast, prostate, colorectal cancer, and
melanoma4-9. The high heterogeneity of the tumour and the very low concentration of
CTCs in peripheral blood (1-10 cells per 10 mL), has made the isolation and quantification
of CTCs a difficult challenge10. The most widely used methods of enrichment rely on
antibody capture of CTCs. More recently, physical properties of the CTCs have been used
to improve the isolation, and currently innovative strategies are being developed with
the aim of improving the capture and detection of these rare cells.
Microfluidic devices can integrate biological processes into microstructures that handle
nano- and pico-litre volumes. This technology is becoming popular because of its ability
to isolate label-free and viable intact CTCs based on their physical properties, such as cell
size. In addition to this, these devices have several advantages in the isolation of CTCs,
which make them promising platforms for implementation in clinical settings. The main
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advantages include low cost, and high-throughput enrichment of CTCs from other cells.
Successful isolation of CTCs from lung and breast cancer patients by physical size, using
a microfluidic device, was reported by Warkiani et al.11, 12. The detection of CTCs in the
blood of these patients at different therapy stages has been shown to be a potential
prognostic marker of treatment efficacy and patient survival.
In this study, microfluidic devices11, 12 have been used, for the first time, to enumerate
CTCs from melanoma patients. Although there are still challenges to be resolved, the
improvement of CTC isolation and detection procedures will ultimately assist in the
understanding of CTC biology, the metastatic process, development of a personalised
guide to treatment efficacy and early prediction of treatment resistance.
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2. LITERATURE REVIEW
2.1 Cutaneous Melanoma
The skin, which is the largest organ in the body, protects us from UV light, injuries and
infections, among other important functions13. The main layers of the skin are the inner
dermal layer and the outer epidermal layer. The dermis contains three different types of
skin cells: squamous cells, basal cells, and melanocytes. Melanocytes are located in the
basal layer of the epidermis and are responsible for melanin pigment production (Figure
1).

Figure 1. Representation of normal skin anatomy. Melanocytes are present in the basal layer of
the epidermis14.

Cutaneous Melanoma (CM) is a highly aggressive skin tumour originating from the
neoplastic transformation of melanocytes. Melanoma occurs principally in the skin;
however, it may also develop in the conjunctiva and uvea of the eye (uveal melanoma),
on various mucosal membranes with pigmented tissues, such as the gastrointestinal
tract, oral or genital membranes, meninges, and in internal organs, such as in the central
nervous system15.
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2.1.1 Epidemiology
Cutaneous melanoma is the most serious form of skin cancer, being responsible for 80%
of skin cancer deaths, even though it represents <5% of all dermatological cancers16. The
incidence of this aggressive type of cancer is increasing worldwide. New Zealand together
with Australia are the countries with the highest incidence of melanoma (Figure 2)17. In
Australia, melanoma was the 4th most commonly diagnosed cancer in 2014 and it is
estimated that 12,960 new cases of melanoma skin cancer were diagnosed in 201518.
A male predominance has been observed after the age of 44 years and in the age group of
20-24 years a female predominance exists in Australia for melanoma over other types of
cancer19. The location of the tumour varies with age, being on the trunk or extremities
more commonly in younger ages, but on head and neck locations in advanced ages20.

Figure 2. Incidence rate of melanoma per 100,000 inhabitants in 2012. Australia has the second
highest incidence worldwide (34.90), behind New Zealand (35.84) followed distantly by
Switzerland (20.30)21.

2.1.2 Aetiology
The first connection between melanoma and the risk factor, UV irradiation, was made by
Henry Lancaster22. Nowadays, we know that sun exposure or artificial tanning is the
major known environmental factor associated with cutaneous melanoma, since
significant mutations have been identified as having direct UVB-induced origin23-26.
Melanoma has the highest prevalence of C>T transition mutations, and this is driven by
UV exposure, resulting in the biggest median number of somatic mutations across all
human cancer types27.
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Trends in melanoma incidence show that Caucasian race, male gender, and older age are
characteristics associated with an increased risk of developing melanoma28. Also, fairskinned individuals with red or blond hair and many freckles are more likely to suffer
from the disease29,

30.

Having a higher number of moles, also increases the risk of

developing melanoma31. Other host factors, such as a personal history of melanoma or
non-melanoma tumours, including other cancers, can increase the risk of developing
melanoma32, 33. Moreover, a weak immune system or having a disease that weakens the
immune system, increases the cancer risk, with a higher incidence of cutaneous
melanoma in patients after organ transplantation due to medical immunosuppression34.
Genetic factors are also involved in melanoma development. About 10% of all melanomas
are estimated to be developed due to hereditary susceptibility35. Since William Norris36
first suggested that melanomas have a hereditary component, the knowledge of
melanoma genetics has advanced significantly. It is now known that having a family
history of melanoma increases the risk 1.74 times compared with a negative family
history of the disease37. Inherited genetic risk factors can be classified by their penetrance
and prevalence38.
Rare high penetrance genetic mutations are present in CDKN2A and CDK4 genes and
prevail in familial melanoma. Both genes are involved in cell-cycle and melanocyte
senescence. As an example, the CDKN2A gene located on chromosome 9p21.3, encodes
for two proteins, p14ARF and p16INK, which control cell cycle entry at the G1 checkpoint
and stabilise p53 expression39. Low penetrance mutations present in the general
population, also referred to as single nucleotide polymorphisms (SNPs), have been
detected in genes involved in hair and skin pigmentation, such as MC1R, ASIP, TYR and
TYRP140-43. Nevertheless, BAP1, POT1, ACD, TERF2IP, and TERT are also considered
melanoma high penetrance inherited risk genes44.
There are also non-inherited gene mutations that increase the risk of melanoma.
Mutations in TP53 tumour suppressor gene mutations caused by UV radiation are present
in melanoma45. Both sporadic and continuing or chronic UV light exposures are linked to
the pathogenesis of melanoma and produce extensive although, different mutational
profiles23, 27. However, more research is needed to better understand the genetics of
somatic and hereditary melanoma.
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2.1.3 Diagnosis
The first step in melanoma diagnosis is the visual characterisation of suspicious lesions.
A nevus (or mole) is a visual delimited zone of chronic lesion found in the skin or
mucosa46. Even though a nevus is considered benign, more than 50% of malignant
melanomas arise from pre-existing nevi47. The principal visual identification of a nevus
which would suggest a malignant change is established by the “ABCDE criteria”. Visual
characteristics of a transformed mole comprise: Asymmetry, a Border that is irregular,
Colour that is uneven, a Diameter longer than 6 millimetres and, a shape, size or colour
that is Evolving (Figure 3). Other early signs of a malignant change could be itching,
ulceration or bleeding. By contrast, nodular melanomas do not follow these criteria. They
have their own "EFG criteria". The lesion is Elevated above the surrounding skin, the
nodule is Firm to the touch and Growing in size.

Figure 3. Melanomas with characteristic asymmetry, border irregularity, colour variation and
large diameter48.

Total body photography is used to assist with the diagnosis of melanoma49. Dermoscopy
is an important tool that can aid in differentiating melanoma from other types of
carcinoma or benign lesions50. Some of the diagnostic techniques available for better
identification of skin cancer include: multispectral imaging, automated diagnosis,
confocal scanning laser microscopy, ultrasound imaging, magnetic resonance imaging,
and optical coherence tomography.
A histological study of a biopsy of a lesion is needed to diagnose malignancy. The
histopathological criteria of melanoma are based on the characteristics of the lesion such
as the extent and penetrance of the tumour or the mitotic rate of the cells in the lesion.
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The discovery of histologic markers that uniquely identify melanocytes in melanoma has
aided melanoma diagnosis. The most commonly used markers are S-100 calcium binding
protein51,

MART-1/Melan-A52,

and

HMB-4553,

54.

However,

new

potential

immunohistochemical markers such as SOX-1055 or MC1R56,57 have been identified to
assist in the classification of melanocytic tumours. Nowadays, a combination of multiple
positive histologic markers and histopathological criteria provides the most reliable
method of diagnosis.
2.1.4 Staging of melanoma
To determine the treatment and the prognosis of a patient with melanoma, staging of the
biopsied material is needed. The American Joint Commission on Cancer (AJCC) updated
the melanoma classifications in 200958 using the most significant prognostic values as
shown in Table 1.
The clinical staging of melanoma is based on the clinical and radiological examination of
the regional lymph nodes and the micro-staging of the primary excised melanoma.
Patients are classified into five main groups. In patients with stage 0 (in situ melanoma),
melanoma is confined to the epidermis and has not invaded deeper skin layers. Patients
with clinical stages I and II, have no evidence of metastases. Stage III patients have
evidence of regional and lymph metastases and stage IV melanoma patients have been
diagnosed with one or more distant metastases59. Pathological staging includes microstaging of the primary melanoma and pathological information about the regional lymph
nodes after partial or complete lymphadenectomy. Both clinical and pathological staging
are important in melanoma diagnosis for correct decisions.
The TNM classification is used to stage patients based on the extent of the primary
tumour (T), the presence or not and the extent of regional lymph node metastases (N),
and the presence or absence of distant metastases (M)60. The T category is further
characterised by defining the presence in the primary tumour of ulceration, mitotic rate,
and tumour thickness as defined by Breslow61. Breslow’s thickness is measured from the
top of the granular layer of the epidermis or from the base of the ulcer to the deepest
dermal invasive cell if the surface is ulcerated. This factor is still the most powerful
predictor of survival62, 63. The mitotic rate within the tumour is the average number of
mitoses per millimetre squared and is also a significant prognostic factor64. Level of
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invasion as defined by Clark et al.65 has been supplanted and is less commonly used for
defining melanoma stages. The N category defines the number of micro or macrometastatic nodes determined by standard immunohistochemical staining against
melanoma markers. The presence of intralymphatic metastasis, including the presence
or absence of satellites or in-transit metastases, is also taken into consideration in this
category. Regional nodal metastasis is defined as a disease confined to one nodal basin,
while patients with distant nodal metastases will be classified as having M stage disease60.
The M category defines the presence of distant metastases in the skin, subcutaneous
tissue, or distant lymph nodes or organs. In addition, elevated serum lactate
dehydrogenase (LDH) is an independent significant predictor of survival outcome among
patients with distant metastases and has been included in this staging category66.
Table 1. Classification of the pathological stage and the main features related to melanoma
progression58.
Survival (%)
5
10
years
years

Pathologic
Stage

TNM

Breslow’s
Thickness
(mm)

Ulceration

No.
Positive
Nodes

Nodal
Type

Distant
Metastasis

0

Tis

-

No

0

-

-

99+

99+

IA

T1a

1

No

0

-

-

95.3

87.9

IB

T1b

1

Yes/Level
IV, V

0

-

-

90.9

83.1

T2a

1.01-2.0

No

0

-

-

89.0

79.2

T2b

1.01-2.0

Yes

0

-

-

77.4

64.4

T3a

2.01-4.0

No

0

-

-

78.7

63.8

T3b

2.01-4.0

Yes

0

-

-

63.0

50.8

T4a

>4.0

No

0

-

-

67.4

53.9

IIC

T4b

>4.0

Yes

0

-

-

45.1

32.3

IIIA

N1a

Any

No

1

Micro

-

69.5

63.0

N2a

Any

No

2-3

Micro

-

63.3

56.9

N1a

Any

Yes

1

Micro

-

52.8

37.8

N2a

Any

Yes

2-3

Micro

-

49.6

35.9

N1b

Any

No

1

Macro

-

59.0

47.7

N2b

Any

No

2-3

Macro

-

46.3

39.2

N1b

Any

Yes

1

Macro

-

29.0

24.4

N2b

Any

Yes

2-3

-

24.0

15.0

N3

Any

Any

4

Macro
Micro
Macro

-

26.7

18.4

M1a

Any

Any

Any

Any

Skin

18.8

15.7

M1b

Any

Any

Any

Any

6.7

2.5

M1c

Any

Any

Any

Any

Lung
Other
Visceral

9.5

6.0

IIA
IIB

IIIB

IIIC

IV
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Cutaneous melanoma can be subdivided into several subtypes, based on common
anatomical locations and different patterns of growth67. Superficial spreading melanoma
(SSM) is the most frequent, followed by nodular melanoma, acral lentiginous melanoma
(ALM) and lentigo maligna melanoma (LMM)59.
2.1.5 Genetic and histopathological changes in melanoma development
Melanocytes progress to a malignant phenotype through several steps, in a process
known as melanomagenesis68 (Figure 4).
Both genetic predisposition and exposure to environmental agents are risk factors for
melanoma development. However, the critical factor that takes place during this
malignant transformation is the progressive accumulation of mutations in genes that
target important pathways of cell proliferation, differentiation, and cell death (Table S1
and Figure S1)69, until finally, melanoma cancer cells acquire the ability to initiate and
sustain angiogenesis.

Figure 4. Biologic events that take place in melanoma progression. The benign nevus commences
a dysplastic transformation, through radial and vertical growth until the metastatic phenotype
arises2.

The Ras/Raf/MEK/ERK mitogen-activated protein kinase (MAPK) signal transduction
pathway is one of the most important pathways in the origin and progression of
melanoma. BRAF is a member of the Raf family of serine-threonine kinases, along with
ARAF and CRAF (also called RAF1). Mutations in the BRAF gene have been described in
40-60%70, 71 of all melanoma cases. Among mutations in the BRAF gene, 80% of the
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mutations result in the substitution of glutamic acid (E) for valine (V) in codon 600,
known as the BRAF V600E mutation; about 16% of mutations in this gene result in a lysine
(K) substitution at the same BRAF V600K codon, and 3% result in an aspartic acid (D) or
arginine (R) substitution that produces a V600D/R codon72. These last two mutant forms
of BRAF tend to be present in melanomas arising in older patients73. All of these mutations
occur as early events in melanomagenesis and result in a mutant protein that is
constitutively active in the cell without the need for activation signals. The consequence
is uncontrolled proliferation and resistance to apoptosis. Nevertheless, the presence of
BRAF mutations in 80% of benign nevi suggests that mutational activation of the MAPK
pathway is a critical step in melanocytic transformation, but alone is insufficient for
melanoma tumourigenesis74.
Mutations in the NRAS gene are present in approximately 15 to 20% of all cutaneous
melanomas75. Tumours that carry NRAS mutations represent a distinct subpopulation,
since BRAF and NRAS mutations generally occur mutually exclusively76,

77.

Together,

NRAS and BRAF mutations are present in about 70% of the most common types of
melanoma78. In addition to these mutations, melanomas (mostly acral melanomas) may
carry mutations that activate the KIT receptor protein tyrosine kinase. The KIT gene is
located on the long (q) arm of chromosome 4. Most KIT mutations are located in exon 11,
which encodes for the juxtamembrane domain, and in exon 13, which encodes for a
kinase domain79.
2.1.6 Treatment and prognosis
The standard treatment for in situ and primary melanoma is wide local excision (WLE) of
the skin and subcutaneous tissues around the melanoma. Removing the melanoma from
the skin by surgery offers the best chance for a complete cure, and this treatment alone
is usually successful in patients categorised as stage 0, I and stage II (71% of all
patients59). Most patients do not need either radiotherapy or chemotherapy, since the
tumour is still localised and metastasis has not been diagnosed. Nevertheless, greater
tumour thickness is associated with an increased risk of local recurrence80. WLE is the
treatment of choice in local recurrences, with consideration given to adjuvant therapy in
some situations59, since there is a risk of systematic or regional metastasis.
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A sentinel lymph node biopsy is a recommended test for stage II patients with thicker
tumours, to see whether a small number of melanoma cells have spread to the nearest
lymph nodes81. If this procedure has positive results, the patient will be diagnosed with
melanoma stage III. Since patients with positive lymph nodes are at high risk for systemic
dissemination, a therapeutic lymph node dissection may be considered.

Figure 5. Survival rates for patients with melanoma stages I through IV59.

In summary, in regards to prognosis, the main clinical and histopathologic predictors of
outcome are Breslow’s thickness, the presence of ulceration, the sentinel lymph node
(SLN) status58 and the presence of distant metastases. Patients diagnosed with different
stages have large differences in their survival rates (Figure 5). Unfortunately, for patients
diagnosed with stage III and IV melanoma, the overall 5 and 10 years survival rates are
drastically reduced relative to those with stages I or II (Table 1).

2.2 Metastatic Melanoma
Approximately 20% of all melanoma patients develop metastases within the first 2 years
of diagnosis2. The typical sites of metastatic disease are the lungs, brain, skin, bone and
liver82. Despite remarkable advances in the treatment of patients with metastatic spread,
only 20% show long lasting responses (>2 years) to current treatments83, 84.
The metastatic process starts with the vertical growth-phase of tumour development
when melanoma cells penetrate the basement membrane, reaching the adjacent dermis
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containing blood vessels and lymph, through which they then spread to form metastases
at a distant location85. Modifications in surface protein expression profiles allow the
detachment of melanoma cells from the primary tumour and provide the ability to
metastasise2. The most important change in cell surface proteins is the loss of Ecadherin/CDH1 and the expression of N-cadherin/CDH2. This transition triggers
alterations in cell adhesion properties86. N-cadherin assists metastatic spread by
allowing melanoma cells to interact with endothelial cells present in the stroma, which
also express N-cadherin and this interaction increases the survival and migration of
melanoma cells87. These alterations indicate the radial-growth phase to vertical-growth
phase transition which is associated with changes in expression of metastasis initiation
genes that allow these tumour cells to migrate and enter blood vessels (intravasation)
(Figure 4)88, 89.
In the next metastatic step, tumour cells can extravasate into distal tissues due to their
low E-cadherin expression levels. Their entry can also be mediated by Rac activation90.
When Rac is activated, the melanoma cells can changes shape and pass between adjacent
cells, assisted by matrix metalloproteinases, which destroy integrins91.
Metastasis progression genes allow melanoma cells to spread to distant organs. These
cells are predominantly apoptotic and necrotic with a relatively short survival time in the
blood of patients with several types of cancer. Immune cells present in blood can prevent
almost all these cells from producing a secondary colony, except the most proficient92.
These tumour cells, released from the primary tumour, extravasate into distant tissues
where they finally develop a secondary tumour when the microenvironment is adequate
(Figure 6). The extravasated cells are commonly found in clusters, covered by
immunologically active cells, such as monocytes or leukocytes, and platelets that may
play a critical role in CTC survival/destruction93,94.
Once melanoma cells arrive at target tissues, cancer cells commence new organ
colonisation and it is thought that, due to their neural crest origin, melanocytes retain
some embryonic plasticity, contributing to their high metastatic potential95. The short
latency of metastatic relapse suggests the existence of multi-organ metastatic
competency in the malignant cells96. Nonetheless, metastatic disease can occur even 10
years after an initial primary lesion97.
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Despite the new advances in understanding metastasis in cancer, the pathways that
melanoma cells use to metastasise are still unclear. Therefore, studies involving
melanoma cells that invade and colonise new organs and tissues will unmask the cellular
and molecular mechanisms underlying the metastasis of melanoma tumours.
Currently, available tools to predict or detect metastatic spread in melanoma are
relatively insensitive, which results in late detection of metastatic disease, significantly
decreasing prognosis and survival. If patients with residual disease that might require
treatment post-surgery were able to be identified earlier, treatment may be more
effective when disease burden is lower4, 98.

Figure 6. Melanoma metastatic process. Metastatic tumour cells detach from the primary site and
penetrate the adjacent parenchyma to reach the blood vessels, adhering to secondary sites such
as the brain, forming new colonies99.

2.2.1 Progression
Metastatic melanoma can be classified into local recurrence, in transit metastasis, nodal
metastasis and distal metastasis, based on the location of metastases.
Local recurrence is defined as a recurrence of melanoma within 2 cm of the surgical scar
of a primary melanoma100. This recurrence can result either from extension of the
primary melanoma, or from the spread via lymphatic or haematogenous vessels101. In
transit metastasis is defined as melanoma deposits within the lymphatic vessels located
more than 2 cm from the site of the primary melanoma. Nodal metastasis involves the
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spread of tumour cells into the lymph nodes. Haematogenous spread of metastatic
melanoma results in development of distal metastasis82.
A variety of sophisticated imaging techniques are used to follow and evaluate patients
with melanoma, including chest radiographs, regional nodal ultrasound imaging,
computerised tomography (CT) scans, positron emission tomography (PET), PET/CT
scans, and brain/spine and hepatic magnetic resonance imaging (MRI) to detect nodal
disease and distal metastases59, 102. However, such technologies are relatively insensitive
and unable to detect micrometastases59. There is therefore, a special need for sensitive
methods that detect serological markers in patients likely to develop distant metastases
and new biomarkers are being studied103, 104. At present the AJCC staging system only
includes LDH blood levels as a prognostic marker for patients with stage IV disease62, and
a more sensitive marker of residual disease is required.
2.2.2 Treatment and prognosis
The choice of therapy for the management of metastatic melanoma depends on the
number of lesions, their anatomical location, and their size. The aims of treatment for
metastatic melanoma are to control the melanoma and to relieve any symptoms, with
curable intentions. Treatments that may be offered include surgery, radiotherapy,
targeted therapies, chemotherapy, immunotherapy and diverse clinical trials of these and
other new drugs individually or in combination are underway.
New combinatorial drug development using targeted therapy and immunotherapy have
revolutionised the clinical management of melanoma patients, improving the quality of
life and the length of survival of patients with stage III or stage IV melanoma105-107.
Nowadays, targeted therapies and immunotherapies are within the standard treatment
choices for metastatic melanoma in Australia and several other countries108.
Targeted Therapy
Since the discovery of activating mutations in the BRAF oncogene in approximately 50%
of melanomas70, there has been notable progress in the development of targeted
therapies for unresectable and metastatic melanoma. The American Food and Drug
Administration (FDA) has now approved the use of BRAF inhibitors vemurafenib and
dabrafenib routinely109 for BRAF positive melanoma. These targeted treatments act as a
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direct inhibitor of BRAF, which is constitutively active due to the presence of mutant
copies of the BRAF gene and thus activates the MAPK pathway regulating tumour growth
gene70.
More recently, MEK inhibitors such as trametinib are administrated in combination with
BRAF inhibitors110. Current clinical trials are testing different combinations of dabrafenib
or vemurafenib with MEK inhibitor drugs as trametinib or cobimetinib111, respectively.
Mutations in NRAS lead to up-regulation of heterogeneous effector pathways, thus
making drug development more difficult and no standard drug is currently available for
patients that carry NRAS mutations. However, new drugs are under investigation in preclinical and clinical trials for NRAS inhibition as well as for alternative BRAF or c-kit
mutations3, 112.
Targeted therapy is effective in most patients. Unfortunately, despite the impressive
initial tumour shrinkage, targeted therapy treatment responses are relatively short-lived
and acquired resistance occurs in a high proportion of cases109, 113. Another disadvantage
of this type of therapy is that significant toxicities are associated with BRAF inhibitors114
and with combination therapies112, 115.
Immunotherapy
Immunotherapy is a promising cancer therapy that aims to strengthen anti-tumour
response in patients with stages III or IV malignant melanoma. In 2011, the FDA approved
the use of immune checkpoint inhibitor, ipilimumab for unresectable or metastatic
melanoma. This antibody binds to cytotoxic T-lymphocyte antigen 4 (CTLA-4) on tumour
cells and blocks its activity, allowing immune cells to target the melanoma cells.
Unfortunately, the patient response rate is low (11.9%) and immune-related adverse
effects are severe and common116.
Alternate immune attenuating checkpoints have been studied and the interaction
between programmed death-1 factor (PD-1) with its ligand (PD-L1) on diverse cells, such
as, antigen presenting cells (APC) or tumour cells, is now routinely targeted for the
treatment of metastatic melanoma107, 117. Pembrolizumab and nivolumab are anti-PD-1
antibodies approved by FDA for the treatment of advanced melanoma in BRAF negative
melanomas or after the failure of previous treatments118,

119.

Anti-PD-1 blockade
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antibodies are now available as first line therapy in BRAF-mutant negative melanoma
patients. The response rate of melanoma patients to nivolumab, and pembrolizumab are
43.7% and 33.7% respectively106, 120. Also, new immune checkpoints inhibitors as well as
the combination of current immune therapies, such as ipilimumab/nivolumab or
pembrolimumab/ipilimumab are being trialled121-123.
Biomarkers
Current therapeutic options for late stage disease are more effective when the disease is
treated in patients with a lower disease burden124, 125. Consequently, melanoma must be
treated at earlier stages to maximise the chances of patient survival. Thus, the ability to
identify signs of melanoma progression prior to overt metastatic disease would be a
valuable clinical tool. The rapidly evolving clinical landscape of melanoma therapy
urgently requires the discovery and the development of reliable and accurate biomarkers
that assist in early detection, diagnosis, staging, prognosis as well as prediction, and
monitoring of treatment response. Also, biomarkers could improve the process of drug
development and response prediction126.
Biomarkers are classified as serum or tissue-specific biomarkers. Several serum
biomarkers have been shown to have prognostic relevance in melanoma. One such
marker routinely used is the enzyme lactate dehydrogenase (LDH) which has been shown
to have prognostic value in later disease stages, and is incorporated in TNM
classification127. However the sensitivity of this marker is reduced during progression128.
Tyrosine and vascular endothelial growth factor (VEGF) were initially reported to have
prognostic value129,

130.

Subsequent studies could not confirm these findings and no

prognostic value is attributed to them. Other diagnostic and prognostic serum
biomarkers are osteopontin131, YKL-40 glycoprotein132, melanoma-inhibitory activity
(MIA) protein133, s100 family protein134 and interleukin-8 (IL-8)135. However, none of
these are commonly utilised in clinical settings.
Tissue specific biomarkers for melanoma are molecules that are over-expressed in
melanoma lesions. Cyclooxygenase-2 (COX-2) is an essential protein in catabolic
metabolism. This protein is induced in tumour cells and a correlation between COX-2
over-expression and Breslow thickness has been found in primary tumours136. Cell
adhesion molecules and matrix metalloproteinases also play an important role in tumour
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progression85. Chondroitin sulphate proteoglycan 4 (CSPG4/HMW-MAA/MCSP) is overexpressed in over 80% of all melanomas and recent studies indicate that the protein is
potentially valuable as a marker of response to treatment or progression137. Currently,
different immune molecules associated with tumour inflammation, such as Galectin-3
may be used to monitor treatment response in melanoma patients138. The prognostic
utility of novel melanoma biomarkers, such as ctDNA, exosomes, or miRNA have been
evaluated with promising results, although none have yet been clinically utilised.
Although ctDNA measurements have been utilised in early detection of melanoma and in
monitoring treatment response, there is a need to find additional biomarkers that can aid
in measuring the disease load and treatment responses. Therefore, the need for
melanoma biomarkers with the ability to provide information early during treatment are
of critical importance when the patient is undergoing systemic treatment.
For patients with advanced melanoma as well as those with localised disease, the analysis
of circulating tumour cells (CTCs) may provide a novel biomarker to guide therapeutic
decisions. Detailed molecular characterisation of melanoma cells circulating in the
bloodstream may yield new insights into the process of melanoma metastasis139.

2.3 Circulating tumour cells (CTCs)
During the last decade, circulating tumour cells (CTCs) have received extensive attention
as new biomarkers. On average, 20 new publications were published each week in 2013
under the key phrase “circulating tumour cell”10, and the number of publications has
continued to increase since then.
The presence of tumour cells circulating in the blood of cancer patients was first reported
by Thomas Ashworth in 1869140. It was observed that these cells were identical to the
cancer cells found in the tumour, leading to the idea that these cells relate directly to
neoplastic development and tumour metastases. The first detection of CTCs was made by
B. Smith141 when technologies had evolved to permit the study of these rare cells.
Circulating tumour cells (CTCs) are cancer cells which detach from primary or metastatic
sites, enter the peripheral blood stream, and may develop into a secondary tumour at
distant sites due to their capacity to enter and exit the bloodstream (Figure 7) 82, 142, 143.
However, only a small fraction of CTCs survive, since they have to escape from immune
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system attack and survive in stressful ambient conditions without cell-matrix
interaction9. CTCs have shown stem-like properties, which might facilitate initiation of
metastatic lesions144, 145. Interestingly, these cells can enter into a state of clinical cancer
dormancy, where, after dissemination, cell division processes may stop and the cell may
persist in a quiescent state, sometimes for more than 10 years146. The amount of time
involved in the dormancy process varies among different kinds of cancers, being
generally relatively short in melanoma (1-2 years)82, although this may vary. CTCs show
malignant features147 not present in healthy cells, and may have less genomic alterations
than primary tumour cells, suggesting that the dissemination may happen in earlier
stages of the disease148.

Figure 7. Metastatic cascade149.
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2.3.1 Biomarker value of CTCs
Circulating tumour cells are derived from the primary and metastatic tumours and their
study provides significant information about the biology and development of the tumour.
Since these cells can be isolated from blood using relatively non-invasive approaches,
their presence in peripheral blood can serve as a “liquid biopsy”. As an independent
prognostic marker, the number of CTCs before, during and after therapy administration
has been shown to be an indication of the length of progression free survival (PFS) and of
overall survival (OS) in various cancers8, 9, 150.
The utility of CTCs as biomarkers for the prognosis and in the monitoring of response to
anticancer therapies has been widely reported for several types of solid cancers. In breast
cancer, CTCs have indicated prognostic value151, 152. Several studies in ovarian cancer
have shown the utility of CTCs in disease monitoring153, 154 with elevated numbers of CTCs
indicating an unfavourable prognosis155. Similar results have been found in other cancer
types such as prostate6, lung156, colorectal157, and hepatocellular carcinoma158. Several of
these studies have used the CellSearch® system (Veridex LCC), the only FDA-approved
CTC enumeration test, which exploits CTCs as a new parameter for estimating prognosis
and monitoring treatment success in metastatic breast, colorectal, and prostate cancer159161.

2.3.2 Biomarker value of CTCs in melanoma
While additional studies are required to further characterise melanoma CTCs and
confirm their clinical utility as a biomarker of treatment response, monitoring the levels
of CTCs before and during melanoma treatment has been shown to be informative with
respect to prognosis and therapy response in melanoma patients.
RT-PCR has been widely used to detect mRNA transcripts associated with melanoma in
blood. Reid et al., examined whole blood RNA from 230 melanoma patients and showed
that the presence of MLANA and ABCB5 transcripts was associated with disease
recurrence and the expression of MCAM was significantly more common in patients with
a negative treatment outcome162. Also, the presence of multiple melanoma markers in
patient blood significantly correlated with their AJCC stage163; the detection of more than
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one marker at baseline and at any time during treatment administration was a negative
prognostic factor for disease-free survival (DFS) and for overall survival (OS)164.
Several studies using immunomagnetic bead-based isolation techniques have also shown
that the number of melanoma CTCs is higher in the blood of patients with advanced
disease4, 165-167. The number of CTCs was also shown to be associated with treatment
failure and shorter median OS if ≥ 2 CTCs are found per 7.5 mL during the time that
patients are receiving treatment168, 169. By contrast, a low CTC count at baseline (< 2 CTCs)
or a decrease in CTCs after treatment initiation was associated with response to
treatments and longer progression free survival (PFS) rates98.
More recently, Gray et al, showed that the presence of CTCs was associated with PFS170.
Interestingly, early-stage patients were generally positive for a single marker compared
to late-stage patients who had larger numbers of CTCs expressing a variety of markers.
Remarkably the differential pharmacodynamic response of CTC subtypes to treatment
was evident in patients treated with BRAF inhibitors (n=16), since the proportion of CTCs
expressing RANK were significantly increased after therapy. In addition, patients with
more than 5 RANK+ CTCs in 4 mL of blood had significantly lower PFS than those with
less than 5 or no RANK expressing CTCs170. Similarly, a preliminary study showed that
the presence of CTCs expressing PD-L1 was associated with response to anti-PD1
blockade171. Thus, prognostic utility might be found not by using total CTCs counts but by
studying specific subpopulations of CTCs.
New experiments with patient-derived xenografts (PDX) are providing new information
that can inform treatment decisions for each patient. Alternately, where tumours are
inaccessible, CTC-derived xenografts or in vitro growth of CTCs may provide a powerful
option for testing of drug efficacy in a patient’s cells. Girotti et al, showed that CTCderived xenografts (CDX) established from advanced stage patients could aid in
monitoring and predicting patient responses to treatments. In fact, they have been
successful in generating CDXs in 6 out of 21 cases (28.6%)172. While the isolation of only
a few CTCs capable of developing xenografts may underestimate the tumour
heterogeneity, these are excellent first steps to addressing several of the issues
surrounding the clinical benefit of CTC characterisation, including the fact that CTCs that
develop xenografts are capable of seeding metastases and therefore harbor significant
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information about the metastatic process. Additionally, further studies characterising
CTC subpopulations prior to injecting them into mice will provide crucial information
about CTC phenotypes that are most likely to develop CDXs.

2.4 Methods for the isolation and detection of melanoma CTCs
The enrichment and detection of CTCs from melanoma patients is extremely challenging,
mainly due to the limited amount of sample available and the very low concentration of
these cells in the peripheral blood, roughly 1 CTC in 106 normal blood cells. In addition,
for melanoma, the difficulties are magnified because common CTC markers, such as
EpCAM, used in CTC enrichment of epithelial cancers, are not commonly expressed by
melanoma CTCs, since melanocytes originate from the neural crest and not the
epithelium173. In fact, melanomas CTCs are a very heterogeneous population of cells4, 170,
174,

yet current techniques used to enrich melanoma cells from blood, commonly do not

consider this fact.
Assays used for CTC identification and characterisation (Figure 8) usually require a
combination of enrichment and detection procedures that aim firstly to increase the
concentration of CTCs in a background of white blood cells and secondly, to enable easier
detection and characterisation of single cells. Despite the actual advances in CTC isolation
and detection technologies, the enrichment of pure CTCs from patient blood remains the
most challenging step to date.

Figure 8. Melanoma CTC isolation and detection technologies.
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2.4.1 Isolation techniques in melanoma
Isolation technologies take advantage of the biological and physical properties of the
CTCs. Biological properties, such as cell surface protein expression, can be useful
characteristics for the isolation of tumour cells from peripheral blood of cancer patients.
On the other hand, cell size, density, total electric charges, and deformability are now the
main physical characteristics used in CTC enrichment175, 176. Thus, CTC isolation assays
can be grouped into label-dependent and label-independent methods177, each method of
enrichment having different advantages and disadvantages (Table 2). These methods are
detailed below.

Advantages

Table 2. Advantages and disadvantages of the label-dependent and label-independent isolation
methods.
Label-dependent methods*

Label-free methods

Lower WBC Background

Do not rely on the expression of surface
markers for CTC isolation

Most commonly used

Integrity of the membrane not affected

The only FDA-approved method for isolation of
CTCs uses this technology

Viability of the cell is maintained
More heterogeneous population of CTCs is
isolated
High recovery efficiency

Disadvantages

Huge heterogeneity in the population of
CTCs isolated
Low heterogeneity in the population of CTCs
isolated

Not widely used in CTCs isolation. More
study is needed

Alteration of membrane integrity

Higher WBC Background

Viability of CTCs is affected
Only CTCs expressing the targeted biomarker are
isolated

*Excluding Negative Immunomagnetic Enrichment

Label-dependent methods
Despite the demonstrated heterogeneity of melanoma CTCs170,

174, 178,

methods for

capture and enrichment of melanoma CTCs have to date relied predominantly on the
expression of one or two known cell surface markers. For example, immunomagnetic
enrichment using magnetic beads coupled with antibodies against known melanomaspecific antigens have been developed to enrich CTCs (positive selection). Alternate
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methods that deplete white blood cells using beads targeting common leukocyte (CD45
or CD34) antigens (negative selection) have also been widely used168, 169, 179, 180.
The CellSearch™ system (Veridex LCC) is the only FDA-approved CTC enumeration test.
This platform involves immunomagnetic bead capture of CTCs followed by cancerspecific marker staining for CTC detection. For breast, prostate and colorectal cancer,
EpCAM is used to capture CTCs followed by staining with cytokeratin150,

181-183.

For

melanoma, however, a different CellSearch™ kit was developed that firstly captures CTCs
expressing melanoma cell adhesion molecule (MCAM) from whole blood and secondly
detects CTCs by immunostaining with anti-MCSP (melanoma-associated chondroitin
sulphate proteoglycan). This kit also immunostains CD45 and CD34 positive cells to
exclude leukocytes and endothelial cells. Khoja and colleagues168 used this melanoma
specific CellSearch™ kit to detect CTCs in 101 metastatic melanoma patients, and found
0-36 CTCs/7.5 mL of blood at baseline prior to treatment, with 60% of patients having no
CTCs and 40% of patients with at least one detectable CTC. Similarly, Rao et al., found 0
to 8,042 CTCs/7.5 mL of blood in 44 melanoma patients: 23% of the patients had two or
more CTCs169.
The need to better capture all melanoma CTCs has driven the development of multiplex
assays where beads linked to cocktails of antibodies against both cancer-related markers
and melanoma-specific cell surface antigens are used.
Freeman and colleagues4 found that using a combination of MCSP, MCAM, ATP-binding
cassette sub-family B member 5 (ABCB5), and cluster of differentiation 271 (CD271)
targeting antibodies captured a significantly higher number of melanoma CTCs in
metastatic melanoma patients than did the use of MCSP or MCAM alone. This finding
demonstrated, for the first time, the high diversity of melanoma CTCs and improved the
sensitivity of bead-based CTC enrichment compared with experiments that target single
markers. Moreover, when using a combination of all of these labelled beads, stage I-II
(n=10) and stage III-IV (n=13) patients showed significantly higher numbers of CTCs than
controls (n=15). More than 1 CTC/mL of blood was detected in 73.9% of patients (range:
0-2.5 CTCs/1 mL of blood). Despite the improvements in sensitivity produced by using a
cocktail of antibodies for CTC capture, spiking experiments revealed that
immunomagnetic enrichment still has low capture efficiency (34%)4.
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In order to improve capture efficiency, a device has been developed more recently that
uses micro-vortices generated by herringbone-shaped grooves to direct cells toward
surface channels coated with a combination of antibodies targeting melanoma-specific
antigens. One study using the herringbone-chip (HB-chip) technology with a combination
of 12 antibodies against melanoma cell surface epitopes detected CTCs by
immunostaining in 79% of patients (8 CTCs/2.5 mL) from a total of 41 metastatic
melanoma patients at various stages of melanoma treatment165.
To avoid capture bias, other methods use negative selection procedures, which capture
leukocytes with anti-CD45 antibody coated beads followed by depletion of white blood
cells using magnetic separation. Systems such as EasySep™ or RosetteSep™ use this
approach. Fusi et al. using the EasySep™ method and detecting CTCs as cells expressing
gp100 and MLANA (melanoma antigen recognized by T cells 1) by flow cytometry, found
87.5% of 32 metastatic melanoma patients had CTCs with a median of 53 CTCs/10 mL of
blood184. Using RosetteSep™, Girotti et al. successfully enriched CTCs and injected them
into NSG mice to generate CDX models172. While the authors have not provided CTC
quantities used to generate the models, it is likely that relatively large numbers of cells
were isolated for successful tumour uptake.
Although negative selection is advantageous for removing cells that do not express the
most common melanoma markers, the purity of CTCs obtained in the enriched fraction is
low, hampering the quantification of CTCs as well as limiting downstream analysis of the
detected CTCs for prognosis. In fact, a spiking experiment comparing the recovery and
purity of CD45 depletion, with positive enrichment, or a combination of both methods,
showed that the greatest recovery was found by using negative selection (58% recovery
rate). However, the greatest purity of the CTC fraction was obtained by using the
combination method (background reduced from 3x107 to 1.5x103of WBCs)179.
The targeting and capturing of CTCs using protein-based enrichment approaches as is
most commonly performed, typically do not allow capturing all CTCs present within a
patient and furthermore, the harsh conditions of the isolation techniques may alter the
integrity and viability of CTCs185, 186, and hence, they are highly critical in functional
studies. Methods that isolate CTCs with high purity, integrity and viability are urgently
needed to determine the real biomarker potential of CTCs in prognosis and in the
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prediction of therapeutic responses in metastatic melanoma patients. Thus, the
development of label-free enrichment technologies is a promising alternative for the
successful isolation of melanoma CTCs.
Label-free methods
To further improve CTC capture, alternative techniques have been developed more
recently, that exploit the larger cell size of melanoma CTCs compared to the remaining
white blood cells. Although it has been shown that melanoma CTCs can have a diverse
range of cell sizes185, most of the CTCs are thought to be larger (10-20 µm) than other
blood components, such as RBCs (6-8 µm), leukocytes (7-12 µm) or platelets (2-3 µm).
Taking advantage of this perceived difference in cell size, the “enrichment by size of
epithelial tumour cells” (ISET®) technique was developed in 2000187. The ISET® system
uses polycarbonate filters with 8 µm diameter circular pores for CTC enrichment and
detection of cells trapped in filters as CTCs involves immunohistochemical staining and
PCR-based genetic analyses. De Giorgi et al. detected CTCs in 29% of patients with
primary invasive melanoma and in 62.5% of metastatic melanoma patients using this
microfiltration system followed by positive detection by real-time RT-PCR for tyrosinase
transcripts. Experiments assessing the sensitivity of this assay showed that ISET® had a
limit of detection of 1 CTC/mL of blood188. However, challengingly, this approach was also
found to isolate benign circulating nevus cells189, suggesting that the molecular analysis
of tyrosinase mRNA by RT-PCR-based systems, cannot reliably distinguish between
benign nevus cells and melanoma cells.
Nevertheless, when using the same ISET enrichment technique, with CTCs defined by
positive immunohistochemistry expression of s100 and negative expression for CD45 or
CD144 (leucocyte and endothelial cell markers, respectively), 57% of 90 metastatic
melanoma patients had detectable CTCs (1-44 CTCs/mL of blood)174.
The OncoQuick® system is another size-based technique that incorporates a filter for
size-based separation of CTCs which is used in conjunction with density-based
centrifugation190. Spiking experiments showed a ≥60% recovery rate when assessed by
qPCR amplification of cytokeratin 8 (KRT8) and 18 (KRT18) RNAs, for 4, 20, 100 and 500
spiked SkMel28 cells. When the OncoQuick® was used for isolation of CTCs from
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melanoma patients, and target RNA transcript levels (MLANA, MIF, TYR, and MITF) were
then quantified by qPCR, results showed that about 1/3 of patients expressed elevated
levels of MIF and MLANA transcripts, in comparison with healthy controls (p<0.0001 and
p<0.001, respectively)191.
Microfluidics
Microfluidic devices control microliter to milliliter volumes in micro-channels of 1 μm to
1000 μm in size. In such conditions, the concentrations of particles/cells can be
effectively controlled, since the flow is strictly laminar192, 193.
At the beginning of the 21st century and the arrival of nanotechnology, many microfluidic
components that work with nanoliter volumes were developed for use in biological
studies194-196. Since then, the field of microfluidics has evolved rapidly, allowing the
manipulation of DNA, RNA, proteins and mammalian cells, as well as single cell assays for
disease diagnosis and prognosis, amongst several other applications193. At present,
microfluidics are valuable for cancer cell investigations due to their high sensitivity, high
throughput, low material consumption, low cost and improved spatial-temporal control.
Microfluidic devices are now proving very useful for isolating CTCs from the blood of
patients with different cancer types.
To date very few studies have utilised microfluidic devices to isolate CTCs from
melanoma patients. The more recently developed CTC-iChip (Figure 9) separates cells
based on size selection using deterministic lateral displacement and inertial focusing
followed by negative depletion in a magnetophoresis. Using this chip, CTCs from
melanoma patients were successfully enriched and detected as positive by staining for
the melanoma antigen recognized by T cells 1 (MART-1)185.
Previous studies identified that CTCs exist as circulating tumour microemboli (CTM) or
CTC clusters in the blood of melanoma patients, raising the idea that cells enter the
bloodstream via collective cell migration, allowing them to survive shear stress and
anoikis forces93, 174. Recently, the Cluster-Chip (Figure 9) was developed particularly to
isolate CTC clusters178. The Cluster-Chip captures CTC clusters of two or more cells
directly from 4 mL of blood, independently of cell tumour-specific marker expression.
This microchip technology relies on the strength of the cluster union as well as on their
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behaviour when a flow speed is applied through a set of triangular pillars. Captured CTC
clusters were identified and detected by immunofluorescence staining in 30% (~0.15
CTCs/mL) of 20 tested metastatic melanoma patients. Interestingly, no correlation was
found between the number of CTC clusters isolated using the Cluster-Chip and the
number of single CTCs isolated using CTC-iChip (n=19)178.

Figure 9. The CTC-iCHIP (left) and Cluster-Chip (right) microfluidic CTC devices178, 185.

Two new spiral microfluidic devices (A5 and Slanted) that allow CTC enrichment based
on Dean Drag forces and the inertial microfluidic phenomenon, have been developed for
CTC isolation11, 12. This separation technology is termed Dean Flow Fractionation (DFF),
and allows a size-based separation using hydrodynamic forces and Dean Drag forces
acting on cells within a laminar flow due to the curvilinear geometry of the
microchannels. The Drag equation calculates the force of drag experienced by an object
due to movement through a fully enclosing fluid. The microenvironment created by these
forces causes different sized particles to travel at different speeds in the liquid phases
with the result that each particle acquires different lateral positions and exhibits different
degrees of focusing inside the chip, allowing a successful size-based separation. Cells are
affected differently by these forces depending on their size, allowing separation through
two different outlets (see Figure 11). Since the size of most of the CTCs are thought to be
larger (10-20 µm)12, 197 than that of other blood components, the DFF-based method
appears suitable for separation of these cell types.
CTC isolation using spiral microfluidic devices that use Dean drag forces198 to separate
tumour cells on the basis of their size11, 12, 199 were tested in this study for the isolation of
melanoma CTCs. The big advantage of this method over label-based isolation techniques
is that it isolates all CTCs regardless of their cell surface proteins. Moreover, there is no
manipulation of cells, which can affect their viability, as well as downstream analyses 185,
186.
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The Slanted microfluidic device
The Slanted spiral microfluidic device relies on inertial microfluidic forces and Dean Drag
forces to separate CTCs from blood cells. This device contains 8-looped spiral
microchannels with one inlet for the sample and two outlets, one inner outlet for
collection of the CTC-enriched cellular fraction (CTC outlet) and one outer outlet for
collection of unwanted blood cells (waste outlet) (Figure 10). The operating principle of
this chip allows large CTCs to stay near the inner channel wall and to be collected from
the inner cell outlet of the chip.
The trapezoidal geometry of the channel cross-section200 increases the resolution of the
separation due to its influence on the formation of Dean vortex cores in the outer walls.
This design is ideally effective when isolating particles with large diameter and low
abundance from smaller and abundant particles. Accordingly, the enrichment of lowabundant CTCs from other blood components is a satisfactory condition for this design.
This Slanted microchip has been shown to efficiently capture cancer cells from blood cells
when using cell lines (MCF-7, T24, and MDA-MB-231) spiked into whole blood. The
results showed an isolation efficiency of ~85%, with a viability of captured cells of
>90%11. High purity was also achieved (400-680 WBCs per mL; ~4 log depletion of
WBCs).

Inner wall
Waste
Outlet

CTC
Outlet

Outer wall

Sample
Inlet

Figure 10. Slanted microchip operating principles for CTC isolation. One inlet for the sample and
two outlets for the enriched cells (CTC outlet) and for the other blood components (waste outlet).
The trapezoidal section is represented as A-A11.

Validation of this isolating principle has been performed in clinical samples. Five patients
with metastatic breast cancer (MBC) and 5 patients with non-small cell lung cancer
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(NSCLC) were studied, as well as 5 healthy controls. All cancer patients had detectable
CTCs (6-57 CTCs mL-1 for MBC and 3-125 CTCs mL-1 for NSCLC)11.
A5 microfluidic device
The A5 chip also relies on Dean Flow Fractionation (DFF) forces to isolate CTCs from
blood. Due to the presence of Dean Forces and inertial lift forces in the curvilinear
channels of the device, a more efficient, high resolution size-based separation is
achieved12 (see Table 3). The microchip consists of 2 inlet and 2 outlet spiral
microchannels of ~10 cm in length. The design of the chip allows larger CTCs to focus
their position inside the channel and be collected through the inner CTC output, while
smaller blood components, less affected by the Drag forces, are removed via the outer
outlet. The blood sample is pumped into the sample inlet, and a sheath fluid is pumped
into the sheath inlet at a higher flow rate. Once the sample is inserted into the device, the
separation process is initiated, with the cells taking different positions inside the
channels, allowing their separation into the outlet portals (Figure 11).
The efficiency of this DFF device was validated using cancer cell lines cells spiked into
whole blood. Three different cell lines (MCF-7, HeLa, and MDA-MB-231) were tested and
a cell recovery of ~85% was achieved using spiked cancer cells. Also, a 2000 fold
leukocyte reduction and a CTC/leukocyte purity of ~10% was achieved from ~2X
dilution of whole blood with saline buffer.
To test the efficacy of this device to isolate CTCs from blood, 20 metastatic lung cancer
patients and 20 healthy controls were tested and CTCs were successfully detected in all
cancer patients (5-88 CTCs/mL)12. The enrichment of CTCs from lung cancer patients
demonstrated the high-throughput capability and high-sensitivity separation of CTCs
using this device.
Moreover, the label-free procedure and the purity of the output sample, allows a
downstream analysis of the live retrieved cells, which include RNAseq, single-cell next
generation sequencing (NGS), quantitative-PCR (q-PCR), FISH or immunofluorescence
staining.
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Figure 11. Optical image of the A5 spiral microfluidic device used in capturing CTCs. Two inlets
for the sample and the sheath flow, and two outlets for the enriched cells (CTC outlet) and for the
other blood components (waste outlet)12.

Recently, a multiplexed version of the A5 chip, that combines three spiral circuits in the
same chip199, has shown better detection of CTCs from breast and lung cancers than those
detected with the FDA-approved CellSearch® method. CTCs were detected in 100% of the
cancer patient samples (n=56), while CellSearch® only detected CTCs in 80% of the
samples201. Furthermore, lower numbers of CTCs were obtained using the CellSearch®
system201. The major advantage of the A5 chip compared to the CellSearch® method, is
the capability of it to be used in different cancers, of both epithelial and non-epithelial
origin, since this approach does not require initial cell surface biomarker selection.

Characteristics

Table 3. Main characteristics of the two microfluidic devices used in this project.
Slanted chip

A5 chip

Number of inlets

1

2

Number of outlets

2

2

Viability test

Yes (>90%)**

Yes (>98%)**

Processing time

1.1 min per 1 mL blood

20 min per 1 mL blood

Flow rates

1700 μL min−1 sample inlet

750 μL min−1 sheath inlet
100 μL min−1 sample inlet

Sample concentration

0.5x

0.5x

Purity

~4 log depletion of WBCs

~3 log depletion of WBCs*

Recovery rates

> 85%**

>85%**

*From whole blood. **Using cell lines.
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In this thesis, the ability of these two novel microfluidic chips to isolate melanoma cells
and CTCs from metastatic melanoma patients was tested for the first time. Three different
settings were studied, namely: single Slanted (1X Slanted), single A5 and double Slanted
(2X Slanted).
2.4.2 Detection techniques
While the above techniques are utilised to isolate/enrich CTCs, optimisation of methods
for the visualisation of the isolated CTCs is also required. A few methods that detect
melanoma CTCs in whole blood from patients, without an enrichment step, have been
reported. For example, Ruiz et al. describes the use of the Epic Sciences platform to detect
intact melanoma CTCs. Erythrocyte lysis was followed by nuclear size analysis and
immunocytochemical identification of melanoma CTCs using a panel of seven anti-MCSP
monoclonal antibodies. Micromanipulation was performed to isolate single CTCs for
whole genome amplification and copy number variation (CNV) analyses. This method
detected 1-250 CTCs in 8 mL of blood (0.5 to 371.5 CTCs/mL of blood) from 22 of 40
metastatic melanoma patients (55%). Interestingly, CNV analyses revealed deletions of
CDKN2A and PTEN, and amplifications of TERT, BRAF, KRAS and MDM2 genes among
others202.
Currently, CTCs present in the enriched fraction are studied and detected by methods
that assess their morphology and/or protein expression using immunocytochemistry
(ICC) or flow cytometry. These techniques stain the cells with a cocktail of antibodies
against cell surface or intracellular markers associated with melanocyte biology or
melanoma pathogenesis4,

170, 203, 204.

Cells are considered tumour cells if positively

fluorescently stained for melanocytic markers, melanoma or tumour-specific markers,
and for the nuclear dye (DAPI or Hoechst 33342), but negative for the common leukocyte
antigen CD45 (a marker present only in leukocytes and not in tumour-derived CTCs).
Using multicolour image analysis with a fluorescence microscope, CTCs are thus
identified as melanocyte/melanoma markers+/CD45-/DAPI+ cells (Figure 12).
In addition, molecular approaches that detect RNA or DNA from enriched melanoma
CTCs, by quantitative real-time PCR (qRT-PCR)205 or droplet digital PCR (ddPCR)206
respectively, have been used for CTC detection and more detailed CTC characterisation.
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New methods based on the presence of elevated telomerase activity are being trialled for
CTC detection207.

MELANOMA
MARKERS

Figure 12. Immunofluorescent CTC staining.

Gray et al. has recently developed a flow-cytometry multimarker approach to detect and
analyse CTCs for the presence of melanoma-associated markers, such as MCSP and
MCAM, in combination with melanoma stem cell markers, such as ABCB5, RANK
(receptor activator of NF-κβ) and CD271170. Using this approach we provided for the first
time, a detailed insight into the diversity of melanoma CTCs, and showed that the
prognostic utility of melanoma CTCs may not rely on the total count of CTCs but on the
CTC subpopulations circulating within an individual. This study indicated that a high
number of melanoma CTCs express melanoma-initiating or stem cell markers (ABCB5
and RANK) while only a very low number of CTCs express melanoma markers MCSP and
MCAM170. Importantly, this study also observed that the common expression of these
melanoma-initiating markers by melanoma CTCs did not correlate with the expression of
these markers in patient-matched tumours, where a rare frequency of melanoma tumour
cells positive for these markers was observed. This finding provides evidence supporting
the hypothesis that CTCs, at least in in melanoma, are derived from rare subpopulations
present in the tumour, which might have the ability to seed new metastases, and not from
the bulk melanoma cells shaping the tumour170.
In summary, the use of microfluidic devices to isolate highly heterogeneous melanoma
CTCs independently of their marker expression could be beneficial. Additionally, the
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application of multimarker immunostaining protocols for the detection of CTCs in the
enriched fraction is of vital importance. Table 4 shows eight of the most common tumour
and melanoma-specific markers used in immunological detection of melanoma.
Table 4. Markers commonly used in immunological detection procedures in melanoma.
Marker

Name or encoding gene

References

Cellular
location

gp100

Also known as premelanosome protein (PMEL), silver locus
protein homolog (SILV), ME20, or Pmel17.

208

Cytosol

MART1

Melanoma antigen recognized by T cells 1. Also known as
Melan-A protein.

52, 209, 210

Cytosol

s100

Different types encoded by the s100b(number) genes.

51, 210

Cytosol

169, 203, 211

Membrane

212-214

Cytosol

4, 170, 215

Membrane

4, 170, 216

Membrane

MCSP
Vimentin
RANK
ABCB5

Melanoma chondroitin sulphate proteoglycan. Also known as
chondroitin sulfate proteoglycan 4 (CSPG4) or neuron-glial
antigen 2 (NG2).
This protein is a type III intermediate filament expressed in
mesenchymal cells, encoded by the VIM gene.
Receptor activator of nuclear factor κβ. Also known as
TRANCE Receptor or TNFRSF11A.
ATP-binding cassette sub-family B member 5. Also known as
P-glycoprotein ABCB5.

In this study, we developed and optimised a protocol for improved staining of CTCs that
utilises three internal markers (gp100, MART1/Melan-A, and s100) and one cell surface
marker (MCSP) to identify CTCs isolated from patient blood using the microfluidic
devices. Lastly, based on Gray et al. findings which show a high number of melanoma CTCs
express the melanoma-initiating or stem cell markers, we have incorporated ABCB5217,
RANK170 and Vimentin213 into our panel, to improve the detection and characterisation of
CTCs after spiral microfluidic enrichment in future studies.
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3. THEORETICAL FRAMEWORK
New biomarkers are required for the early detection of disease progression and
therapeutic response in metastatic melanoma patients. Circulating tumour cells (CTCs)
have been shown to be a useful biomarker of cancer development and for therapeutic
response guidance16, 218, 219. However, isolation of melanoma CTCs is very challenging
because of the low quantities of CTCs in blood and the heterogeneity of cell surface
markers expressed by melanoma CTCs10, 170, 174. These challenges have limited the utility
of CTCs as biomarkers in patients with metastatic melanoma.
Microfluidic chips can successfully isolate CTCs with high integrity from different cancer
types11,

199, 201,

with few used in melanoma to date178,

220.

The ability of microfluidic

devices to isolate label-free and viable CTCs with high efficiency and low cost has
prompted their use in this study for isolation of heterogeneous melanoma CTCs170.
The detection of CTCs using melanoma-specific markers has previously indicated the
extreme heterogeneity of these cells170, 174, 220. To better understand their biology and the
differential response of heterogeneous CTCs to treatment, immunostaining protocols that
combine multiple cancer, melanocyte and melanoma-specific markers are developed and
optimised here to assist with detection of diverse CTC subpopulations isolated from
metastatic melanoma patients using a label free device4, 170.
The optimisation of live and label-free CTC isolation procedures using available
microfluidic devices as well as the optimisation of approaches for the detection of a broad
spectrum of CTC subtypes from metastatic melanoma patients is of importance for the
study of melanoma progression and therapeutic efficacy.
The overall aim of this study was to determine the effectiveness of the isolation of
melanoma cell lines using three microfluidic approaches (1X Slanted11, A512 and 2X
Slanted), and the potential for these devices to be utilised for the isolation of pure CTCs
from the blood of metastatic melanoma patients. Furthermore, the study aimed to assess
additional cellular markers to be used in immunostaining that can improve the detection
of CTCs isolated from melanoma patients using microfluidic devices. The implementation
of this label-free method in isolating CTCs will facilitate downstream functional studies
as well as phenotypic and genomic characterisation of melanoma CTCs.
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3.1 Hypothesis
Spiral microfluidic devices allow the isolation of circulating melanoma cancer cells
(CTCs) from the blood of metastatic patients.

3.2 Aims
1. To measure the efficiency of three spiral microfluidic approaches to isolate differently
sized melanoma cell lines spiked into healthy control blood.
In order to determine for the first time the ability of the spiral microfluidic devices to
isolate melanoma cells, spiking experiments were performed to compare the recovery
rates after processing through single Slanted (1X Slanted), single A5 and double Slanted
(2X Slanted). The recovery efficiency and purity were analysed for each method.
2. To detect CTCs from metastatic melanoma patients enriched by the 2X Slanted device,
using an optimised immunostaining protocol.
After enrichment through the 2X Slanted device, protocols for detection of CTCs from
patient samples, such as cytospin conditions and immunostaining were optimised. Blood
samples from 10 metastatic melanoma patients were then analysed for the presence of
CTCs after enrichment using the 2X Slanted microfluidic device, followed by the revised
immunostaining protocol. In addition, 3 healthy volunteers were used as negative
controls.
3. To test additional cellular markers that can be used in immunostaining assays for
optimisation of detection and phenotypic characterisation of heterogeneous melanoma
CTCs.
In order to further improve the detection of CTCs, three additional cancer stem-cell and
tumour markers were tested, Vimentin, RANK, and ABCB5. To assess their ability to
improve CTC detection, the expression of these markers was assessed by
immunocytochemistry in three melanoma cell lines, either alone or when spiked into
blood from healthy volunteers.
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4.1 Aim 1. To measure the efficiency of three spiral microfluidic
approaches to isolate differently sized melanoma cell lines spiked into
healthy control blood.
4.1.1 Experimental Design and Methods
Figure 13 illustrates the key steps followed in the preparation and processing of the
samples in order to determine the efficiency of different spiral microfluidic approaches
to isolate spiked melanoma cells with different cell sizes spiked into blood samples from
healthy donors. For this, three microfluidic approaches were used: single Slanted (1X
Slanted), single A5 and double Slanted (2X Slanted), by which the sample is processed
twice through the Slanted device. The last setting was tested with the aim of improving
WBC depletion rates.

Figure 13. Overview of the methodology of sample preparation and processing. Firstly, the
spiking of melanoma cells into healthy blood samples was completed (A) prior to processing the
blood using three different approaches (B). Finally, the recovery analysis (C) determined the
recovery rates for each spiral microfluidic approach by counting total red labelled cells recovered
in the enriched fraction.

Cell lines and cell culture
Two melanoma cell lines (A2058 and SKMEL5) obtained from the American Type Culture
Collection (ATCC, USA) were used in spiking experiments. Previous studies in our
research laboratory have identified melanoma cell lines A2058 and SKMEL5, as the cell
lines with the smallest and largest cell size respectively, from a panel of six melanoma cell
lines (Figure 14).
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Figure 14. Melanoma cell line heterogeneity in size determined by flow cytometry.

Cells lines were cultured in high-glucose Dulbecco’s modified Eagle’s medium (DMEM)
(Thermo Fisher Scientific, USA) supplemented with 10% foetal bovine serum (FBS)
(Invitrogen, USA). The cultures were maintained at 37 C in a humidified atmosphere
containing 5% (v/v) CO2 until 80% confluence. Cell lines were passaged every 72 hours
as per ATCC guidelines. Sub-confluent monolayers were dissociated using 5mM
Ethylenediaminetetraacetic acid (EDTA) in DMEM. Viability and cell counts of cell
cultures at every passage were determined using a Vi-CELL XR cell counter (Beckman
Coulter, USA). Only cell cultures with a viability higher than 80% were used in subsequent
experiments.
CellTrackerTM labelling
For the counting and detection of recovered cells after processing melanoma spiked
blood samples through the three microfluidic approaches, melanoma cell cultures were
firstly stained with CellTracker™ Red CMTPX dye (Thermo Fisher Scientific, USA), which
passes freely through cell membranes into cells, and stains all cells similarly. For the
CellTracker™ staining, A2058 and SKMEL5 cell cultures were washed twice with PBS
(137 mM NaCl, 10 mM Phosphate, 2.7 mM KCl, pH of 7.4) after removing the culture media
followed by incubation in 2 mL of DMEM, containing 2 µL of CellTracker™ dye (1µM) for
45 min at 37 C in a humidified atmosphere containing 5% (v/v) CO2. After incubation,
the staining media was removed and two washes with a PBS solution were performed.
Cells were dissociated using a 5mM EDTA in DMEM solution for 5 minutes and 2 mL of
10% FBS/DMEM media was added to inhibit dissociation activity. After this, the cells in
suspension were ready for spiking purposes. Staining of cells was confirmed under an
inverted fluorescent microscope (Eclipse Ti-E, Nikon®, Japan).
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Blood collection
For all experiments, healthy donors provided signed consent forms, previously approved
by the Human Research Ethics Committees at ECU (No.11543). The blood was drawn by
phlebotomists into Vacutainer tubes containing EDTA anticoagulant (Becton-Dickinson,
USA), after discarding the first 2 mL to avoid epithelial contamination.
Spiking experiments
For spiking experiments, in order to mimic the low numbers of CTCs commonly present
in melanoma patients, 50 x CellTracker-stained melanoma cells derived from either
A2058 or SKMEL5 cell cultures were manually counted and picked with a pipette under
the microscope and collected cells were spiked into 8 mL of blood, in triplicate
experiments. Then, red blood cells were lysed using red blood cell (RBC) lysis buffer (140
mM NH4Cl, 17 mM Tris, pH 7.65) at a 1:10 vol/vol ratio for 5 min at room temperature
with continuous gentle mixing. The lysed RBCs were removed after centrifugation at 300
g for 10 min, and the nucleated cell fraction was washed twice with 20 mL of PBS before
resuspension into 16 mL (0.5X concentration) of a PBS solution containing 0.5% bovine
serum albumin (0.5% BSA-PBS) to prevent non-specific adsorption and bubble formation
during processing. Nucleated cells from blood were processed through the spiral
microfluidic devices using the three microfluidic approaches: single Slanted (1X Slanted),
single A5 and double Slanted (2X Slanted).
Determination of the recovery rate of melanoma cells spiked into blood and isolated
using the microfluidic devices
Prior to sample processing, the biochips were washed with ethanol 70% and PBS before
being primed with PBS/0.5% BSA using a syringe pump (PHD 2000, Harvard Apparatus,
USA) for around 2 min at a flow rate of 1 mL min−1 for each solution. For isolation of
melanoma cells, the processed blood samples containing spiked melanoma cells were
placed in a 20 mL syringe (20 mL Luer-Lok, BD™, USA) and pumped through the device
using a syringe pump connected to the microchannel device with flexible Tygon® tubing
(Cole-Parmer, USA) (Figure 15).
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Figure 15. The workstation setup for melanoma cell or CTC separation. The blood after
erythrolysis is pumped through the microfluidic device using a syringe pump.

As recommended in literature11, 199, the flow rate for the input flow of the Slanted chip
was 1700 μL min−1. For the A5 spiral microfluidic device, a flow rate of 750 μL min−1 was
used for the sheath inlet and 100 μL min−1 for the blood inlet. 0.5% BSA in PBS buffer was
used for the sheath inlet in the experiments with the A5 microfluidic device11, 221.
After processing the sample through 1X Slanted, A5 alone, or 2X Slanted, cells were
collected from two outlets: one containing the recovered melanoma cells (CTC outlet) and
the other containing the remaining white blood cells (waste outlet) (Figure 10 and 11).
For the 2X Slanted approach, the CTC outlet sample, retrieved after processing through
Slanted the first time, was resuspended in 6 mL of 0.5% BSA/PBS, changed into a syringe
and pumped directly into the inlet of the Slanted chip using the conditions mentioned
previously.
In order to determine the recovery rates, the cellular fraction from the CTC outlet was
evaluated and counted for each experiment. For this, cells in the CTC fraction were
separated from the supernatant by centrifugation at 500 g for 5 min. The cell pellet was
resuspended and transferred to a 12-well plate (Greiner Bio-One, Austria). Using the NISElements High Content Analysis software, version 4.2 using an inverted fluorescent
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microscope (Eclipse Ti-E, Nikon®, Japan), cells were identified individually by studying
both their morphology, and their CellTracker™ staining pattern to allow their correct
identification as a spiked melanoma cell. A TRITC filter with set excitation and emission
(Ex/Em) wavelengths of 555/607 nm, was used for red fluorescence identification.
The recovery rate for each experiment was determined as the number of red-labelled
cells recovered, divided by the number of spiked cells per experiment.
Determination of the purity of the enriched fraction
In order to determine the purity of the recovered fraction, 8 mL of blood from healthy
donors was run in triplicate through 1X Slanted, A5 and 2X Slanted, counting the WBC
content with a Neubauer chamber (Hawksley, England), before and after the microfluidic
isolation. For this, 10µL of a previous dilution of the enriched fraction containing the
isolated melanoma cells, mixed 1:1 in Trypan Blue (Sigma, USA) was placed in the
chamber. Total cells present in the four main corner squares were counted. Sample
concentration was calculated as:
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑥 104 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
= 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠/𝑚𝐿
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠

For the 2X Slanted approach, WBCs content was determined before, after one round and
after two rounds. WBCs counts were log10 transformed and depletion rates were
calculated by comparing the total number of cells after microfluidic processing to the
initial WBC count.
Statistical analysis
To test whether the data was approximately normally distributed, a Shapiro-Wilk’s test
was used (p>0.05). One-way ANOVA was used to determine if it exists an overall
difference between the groups analysed and Tukey post-hoc analysis was used to
determine if the efficiency of the Slanted device to deplete WBCs from the total after 2X
Slanted enrichment of control samples in particular, was significant. These analyses were
performed using Microsoft Excel, SPSS Statistical software (version 22.0) and GraphPad
Prism (version 5.0). Statistical significance was reached with a P <0.05.
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4.2 Aim 2. To detect CTCs from metastatic melanoma patients enriched
by the 2X Slanted device, using an optimised immunostaining protocol.
4.2.1 Experimental design and Methods
In order to confirm that the 2X Slanted method was able to isolate CTCs from metastatic
melanoma patients, an optimised multimarker immunostaining assay was developed that
included melanocyte/melanoma-specific cell surface markers and intracellular markers.
To ensure that the majority of melanoma CTCs isolated by this device were successfully
transferred onto glass slides for further immunostaining detection, the cytospin and
immunostaining processes were optimised prior to processing of blood samples from
metastatic melanoma patients. The steps followed for the enrichment and detection of
melanoma CTCs from the blood of metastatic melanoma patients are indicated in the
schematic below (Figure 16).

Figure 16. Flowchart of CTC enrichment and detection procedures. The processed blood from
the melanoma patients was run through the 2X Slanted microfluidic device for CTC enrichment
(A). The CTC output from the microfluidic enrichment was transferred onto slides by
centrifugation (B) for optimisation of the subsequent immunostaining process (C). Finally, the
CTCs were identified using an automated fluorescence microscope (D).

Cell lines and cell culture
A2058 melanoma cell line was used in the cytospin and staining optimisation processes.
This melanoma cell line was obtained from the American Type Culture Collection (ATCC,
USA).
WBCs isolation from healthy volunteers
Healthy donors provided signed consent forms, previously approved by the Human
Research Ethics Committees at ECU (No.11543). The blood was drawn by phlebotomists
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into Vacutainer tubes containing EDTA anticoagulant (Becton-Dickinson, USA), after
discarding the first 2 mL to avoid epithelial contamination.
Then, red blood cells were lysed using red blood cell (RBC) lysis buffer at a 1:10 vol/vol
ratio for 5 min at room temperature with continuous gentle mixing. The lysed RBCs were
removed after centrifugation at 300 g for 10 min and the nucleated cell fraction was
washed twice with 20 mL of PBS before resuspension into 10 mL PBS. Cells were then
counted using a Vi-CELL XR cell counter (Beckman Coulter, USA) before proceeding with
the spiking experiments.
Cytospin optimisation
In order to confirm that the cells enriched by the 2X Slanted device are entirely
transferred onto glass slides, the ability of the cytospin to improve recovery of spiked
cells was tested. For this, and for the following protocol described in section 4.1.1, 50 cells
from the melanoma cell line A2058 were stained with CellTracker™ and mixed with
approximately 5x103 WBCs isolated from a healthy control. The cells were pelleted and
carefully resuspended in a fixing solution of 4% PFA for 10 min at room temperature.
Thereafter, cells were transferred into a cytofunnel (Shandon™ Single Cytofunnel™ with
Brown Filter Cards, Thermo Fisher Scientific, USA) precoated with PBS supplemented
with 0.5% BSA (0.5% BSA /PBS), after washing the tube. Cells were cytospun onto glass
slides (Cytospin™ 4, Thermo Fisher Scientific, USA; Figure 17) for 5 min, at medium
acceleration, and different centrifugation speeds: 1000, 1300, 1600, and 2000 rpm to
identify the optimal centrifugation speed required. Finally, cells were stained with DAPI
(4',6-diamidino-2-phenylindole) and mounted using ProLong® Gold Antifade Mountant
with DAPI reagent (Thermo Fisher Scientific, USA). The slides were stored at 4ᵒC until
analysis by microscopy. Slides were scanned using an automated inverted fluorescent
microscope (Eclipse Ti-E, Nikon®, Japan; Figure 18), and analysed using the NIS-Elements
High Content Analysis software, version 4.2. In order to be qualified as a spiked A2058
cell, the cell needed to have a positive signal for the nuclear DAPI staining and also be
positive for the CellTracker™ Red dye. The speed that offered the best recovery, was
tested in triplicate in order to ensure consistency.
In order to study the recovery rate after microfluidic enrichment followed by the
cytospin, 50 x A2058 CellTracker™ cells were spiked in triplicate experiments into 8 mL
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of whole blood from healthy donors. After treating the blood plus melanoma cells with
lysis buffer and processing the sample through the 2X Slanted device as explained in
section 4.1.1, the enriched fraction was cytospun using the speed 2000 rpm as this
provided the highest recoveries without affecting the cell morphology. The number of
recovered cells in each sample was analysed as described in the previous paragraph.

Figure 17. Cytospin 4® centrifuge used in transferring cells onto slides.

Optimising the detection of cells processed through the microfluidic device
Previous studies in our laboratory have described three melanocyte/melanoma-specific
markers highly expressed in melanoma cell lines. These markers (gp100, Melan-A, s100,
and MCSP) were previously utilised in a multimarker approach to identify melanoma
CTCs after immunomagnetic enrichment. In order to test the effectiveness of this
multimarker immunostaining approach in detecting melanoma cells processed through
the cytospin, 50 x A2058 cells and approximately 5x103 WBCs isolated from healthy blood
were mixed, pelleted and carefully resuspended in 4% PFA for 10 min at room
temperature. Then, cells were cytospun as previously detailed (Cytospin™ 4, Thermo
Fisher Scientific, USA; Figure 17) for 5 min, at medium acceleration, and 2000 rpm. Cells
were again fixed with 4% PFA for 10 mins and incubated in a blocking buffer containing
10% NDS, 3% BSA and 0.2% Triton X-100 (Sigma-Aldrich, USA) in PBS
(10%NDS/3%BSA/0.2%TX-PBS) for 15 mins. Cells were then incubated in blocking
buffer for 1 hour at room temperature, containing the multimarker panel:
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-

Three internal markers (referred in this document as ‘MEL-staining’): anti-gp100
antibody (clone EPR4864, Abcam), anti-Melan-A/MART1 antibody (clone
EP1422Y, Abcam), and anti-s100 (EP1576Y, Abcam).

-

One surface marker: anti-MCSP antibody conjugated to Alexa Fluor® 647 dye
(MCSP-647; clone 9.2.27, BD Pharmingen).

-

One leukocyte-specific marker: anti-CD45 antibody conjugated to Phycoerythrin
(CD45-PE; clone HI30, BD Pharmingen).

-

(See Table 6 for antibody dilution information).

After incubation, cells were washed three times with 0.2% TX-PBS solution, and
incubated in blocking buffer with a secondary donkey anti-rabbit IgG antibody
conjugated to Alexa Fluor® 488 dye (R488; Abcam) for internal marker staining. Finally,
cells were stained with DAPI and mounted using ProLong® Gold Antifade Mountant with
DAPI reagent (Thermo Fisher Scientific, USA). Once immunostaining was completed,
slides were stored at 4ᵒC.
Slides were scanned using an automated inverted fluorescent microscope (Eclipse Ti-E,
Nikon®, Japan; Figure 18), and analysed using the NIS-Elements High Content Analysis
software, version 4.2.
Internal markers (‘MEL- staining’) were identified using a FITC filter with set excitation
and emission (Ex/Em) wavelengths of 470/535 nm with an exposure time of 700 ms. The
signal produced by the cell membrane MCSP-647 dye was identified using a Cy5 filter
(Ex/Em = 640/720 nm) with an exposure time of 1 s. On the other side, CD45-PE stained
leukocytes were identified using a TRITC filter (Ex/Em = 555/607 nm) with an exposure
time of 500 ms. Nuclear staining was identified with a DAPI filter (Ex/Em = 395/460 nm)
with an exposure time of 200 ms.
In order to be qualified as A2058 melanoma cell, the cell needed to have positive
expression for the nuclear DAPI staining and also be positive for either the internal
melanoma markers (‘MEL-staining’) or MSCP staining, but negative for the CD45
leukocyte-specific marker.
Furthermore, the recovery rate of the whole process (Slanted enrichment, cytospin and
immunostaining) was studied by spiking 50 cells in triplicate experiments into 8 mL of
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blood from healthy donors. After treating whole blood with RBC lysis buffer and
processing the sample through the 2X Slanted device as explained in section 4.1.1, the
enriched fraction was cytospun and stained, as described in the above paragraph.
Patients and blood collection
Blood from 10 metastatic melanoma patients, collected prior to clinical treatment with
targeted inhibitors or immunotherapies, was included in this study (Table 5). Healthy
volunteers and melanoma patients signed consent forms previously approved by the
Human Research Ethics Committees at ECU (No.11543) and Sir Charles Gairdner Hospital
(SCGH, No. 2013-246). The blood was drawn by phlebotomists into one 8 mL Vacutainer
tube containing EDTA anticoagulant (Becton-Dickinson, USA), after discarding the first 2
mL to avoid epithelial contamination.
Table 5. Demographic information of metastatic melanoma patients.
PATIENTS’ CHARACTERISTICS
n % of total
Total patients enrolled
10
Age at enrolment (years)
Median
68
Range 46 - 78
Gender
Male
6
60%
Female
4
40%

CTC enrichment using the 2X Slanted enrichment
An EDTA tube containing 8 mL of blood from a total of 10 metastatic melanoma patients
and healthy volunteers was used for analysis. Blood samples were processed, within 24
hours after collection. Whole blood was treated with RBC lysis buffer and washed twice
with 20 mL of PBS before resuspension in 16 mL (0.5X concentration) of 0.5% BSA/PBS.
Once the blood had been processed and resuspended into PBS/0.5% BSA, the 16 mL
nucleated fraction derived from 8 mL of blood was processed through the Slanted using
a flow rate of 1700 μL min−1. The cellular fraction of the CTC outlet from the first round
was resuspended in 6 mL of 0.5% BSA/PBS solution and processed again through the
same Slanted device using an input flow rate of 1700 µL min-1.
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CTC detection from the enriched fraction
The cells recovered in the CTC outlet after processing the sample twice through the
Slanted microfluidic device, were immediately pelleted and fixed by 10 min incubation
with 4% PFA. After that, cells were cytospun (Cytospin™ 4, Thermo Fisher Scientific) onto
glass slides at 2000 rpm for 5 mins at medium acceleration. Cells were again fixed with
4% PFA for 10 mins and incubated in a blocking buffer (10%NDS/3%BSA/0.2%TX-PBS)
for 15 mins. Cells were then incubated in blocking buffer for 1 hour at room temperature,
containing the multimarker panel:
-

Three internal markers (‘MEL-staining’): anti-gp100 antibody (clone EPR4864,
Abcam), anti-Melan-A/MART1 antibody (clone EP1422Y, Abcam), and anti-s100
(EP1576Y, Abcam).

-

One surface marker: anti-MCSP antibody conjugated to Alexa Fluor® 647 dye
(MCSP-647; clone 9.2.27, BD Pharmingen).

-

One leukocyte-specific marker: anti-CD45 antibody conjugated to Phycoerythrin
(CD45-PE; clone HI30, BD Pharmingen).

-

(See Table 6 for antibody dilution information).

After incubation, cells were washed three times with 0.2% TX-PBS solution, and
incubated in blocking buffer with a secondary donkey anti-rabbit IgG antibody
conjugated to Alexa Fluor® 488 dye (R488; Abcam) for the internal markers staining.
Finally, cells were stained with DAPI and mounted using ProLong® Gold Antifade
Mountant with DAPI reagent (Thermo Fisher Scientific, USA). Once immunostaining was
completed, slides were stored at 4ᵒC.
Slides were scanned using an automated inverted fluorescent microscope (Eclipse Ti-E,
Nikon®, Japan; Figure 18), and analysed using the NIS-Elements High Content Analysis
software, version 4.2 using the same fluorescent filters and exposure times as indicated
above.
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Figure 18. Eclipse Ti-E, Nikon® fluorescent automated microscope and software used in CTC
quantification and analysis.

Additionally, cell sizes were also measured with this software. Background subtraction
parameters for each marker derived from the immunostaining of A2058 melanoma cells
spiked into WBC fractions, were stringently applied to all stained slides of CTC samples
from patients. For this, the fluorescent intensity cut-offs applied in the analysis were:
2000 LUTs for FITC filter, 300 LUTs for Cy5 filter, 2000 LUTs for TRITC filter, and 1500
LUTs for DAPI filter.
In order to be identified as a CTC, the cell needed to have positive expression for nuclear
DAPI staining and also be positive for either the internal melanoma markers (‘MELstaining’) or MSCP staining, but negative for the CD45 leukocyte-specific marker.
Table 6. Antibody information (Aim 2).
Antibody

Antigen
Location

gp100

Cytosol

MART1

Cytosol

S-100

Cytosol

MCSPAF647

Membrane

CD45-PE

Membrane

Donkey
anti-rabbitR488

n/a

Vendor
Abcam
Clone EPR4864
Abcam
Clone EP1422Y
Abcam
Clone EP1576Y
BD
Pharmingen™
Clone 9.2.27

Dilution used
1/50
1/50
1/500

Notes
Included in the
Multimarker Panel
Included in the
Multimarker Panel
Included in the
Multimarker Panel

1/200

Included in the
Multimarker Panel

BD
Pharmingen™
Clone HI30

1/20

Leukocyte-specific
antibody

Abcam
ab150065

1/500

Anti-rabbit
Secondary Polyclonal
Ab
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Determination of the purity of the enriched fraction
In order to determine the purity of the recovered fraction after using the 2X Slanted
approach, WBC content was determined in five patients, before and after one round of
enrichment by counting cells in a Neubauer chamber (Hawksley, England). For this, 10µL
of a previous dilution of the enriched fraction containing the isolated melanoma cells
were mixed 1:1 in Trypan Blue (Sigma, USA) was placed in the chamber. Total cells
present in the four main corner squares were counted. Sample concentration was
calculated as:
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑥 104 𝑥 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟
= 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠/𝑚𝐿
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑠𝑞𝑢𝑎𝑟𝑒𝑠

After the second round of enrichment, WBC count was performed on the immunostained
slides using an inverted fluorescent microscope equipped with the NIS-Elements High
Content Analysis software, version 4.2. This software allows identification and
quantification of single DAPI stained circular profiles with a set maximum area of 350
µm2. WBCs counts were log10 transformed and depletion rates were calculated by
comparing the total number of cells after microfluidic processing to the initial WBC count.
Statistical analysis
To test whether the data was approximately normally distributed, a Shapiro-Wilk’s test
(p>0.05) was used. One-way ANOVA was used to determine if it exists an overall
difference between the groups analysed and Tukey post-hoc analysis was used to
determine if the efficiency of the Slanted device to deplete WBCs from the total after 2X
Slanted enrichment of melanoma patient samples in particular, was significant. These
analyses were performed using Microsoft Excel, SPSS Statistical software (version 22.0)
and GraphPad Prism (version 5.0). Statistical significance was reached with a P <0.05.

4.3 Aim 3. To test additional cellular markers that can be used in
immunostaining assays for optimisation of detection and phenotypic
characterisation of heterogeneous melanoma CTCs.
4.3.1 Experimental design and Methods
Figure 19 shows the main steps followed in order to determine melanoma markers are
expressed in melanoma cells and potentially expressed by CTCs from melanoma patients.
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Figure 19. Overview of the process for all staining experiments. Melanoma cells were either
seeded on coverslips or mixed with WBCs and cytospun onto glass slides (A). The cells were
stained with the chosen biomarkers by immunocytochemistry (B). Finally, automated
fluorescence scanning allowed the analysis of the immunostained cells with different markers
(C).

Immunocytochemical staining of additional melanoma cell markers most commonly
expressed in melanoma cell line cells for optimal melanoma cell/CTC detection
The optimisation of the immunostaining protocol by the addition of supplementary
melanocyte/melanoma markers to the staining protocol for detection of an increased
number of melanoma cells was completed using cells derived from melanoma cell lines.
The expression of three additional markers (Vimentin, RANK and ABCB5) was assessed
in A2058, WM164 and SKMEL5 melanoma cell lines in order to identify additional
markers expressed in all or in the majority of the melanoma cells derived from cell lines,
so as to best identify additional markers that can be used to stain and identify
heterogeneous melanoma cells.
Firstly, the optimal concentration of the antibodies was assessed by determining the
concentration that provided optimal staining with minimal background staining using
A2058 cells cytospun and stained on cover slips. The optimal concentration was then
used to stain another two cell lines to confirm the expression pattern of the marker in
multiple melanoma cell lines.
Cell lines and cell culture
SKMEL5, A2058 and WM164 melanoma cell lines were used. The melanoma cell line
WM164 was kindly provided by Professor Meenhard Herlyn from The Wistar Institute
(Philadelphia, USA) and A2058 and SKMEL5 melanoma cell lines were obtained from the
American Type Culture Collection (ATCC, USA) (Figure 20).
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Figure 20. Microscopic bright field caption of A2058 cells (A), WM164 cells (B), and SKMEL5
cells (C) in culture. All images taken at 10x magnification. Scale Bar: 200 µm.

Cells were seeded on sterile square glass cover slips in 12-well cell culture plates (Greiner
Bio-One, Austria) and incubated for 24 hours in high-glucose DMEM (Invitrogen, USA)
supplemented with 10% FBS (Invitrogen, USA) and maintained at 37 C in a humidified
atmosphere containing 5% (v/v) CO2.
WBCs isolation from healthy volunteers
Healthy donors provided signed consent forms, previously approved by the Human
Research Ethics Committees at ECU (No.11543). The blood was drawn by phlebotomists
into Vacutainer tubes containing EDTA anticoagulant (Becton-Dickinson, USA), after
discarding the first 2 mL to avoid epithelial contamination.
Red blood cells were lysed using red blood cell (RBC) lysis buffer at a 1:10 vol/vol ratio
for 5 min at room temperature with continuous gentle mixing. The lysed RBCs were
removed after centrifugation at 300 g for 10 min and the nucleated cell fraction was
washed twice with 20 mL of PBS before resuspension into 10 mL PBS. Cells were then
counted using a Vi-CELL XR cell counter (Beckman Coulter, USA) before proceeding with
the spiking experiments.
Immunofluorescent staining of the melanoma cell lines
Attached cells were washed with PBS and fixed with 4% paraformaldehyde (PFA) for 10
minutes at room temperature and then washed 3 times with PBS. Cell surface and
intracellular markers were stained using different immunostaining protocols, as
described below.
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RANK cell surface marker was stained by incubating the cells with anti-RANK mouse
antibody (clone 80704, R&D Systems) diluted in 3% BSA/PBS for one hour at room
temperature. Antibody dilutions of 1/20, 1/50, and 1/100 were tested.
Subsequently, melanoma cells were washed 3 times with PBS and incubated with a
secondary donkey anti-mouse IgG polyclonal antibody conjugated to Alexa Fluor® 488
dye (M488; Abcam) diluted 1/500 in 3%BSA/PBS and kept for 15 min at room
temperature in the dark.
Intracellular markers were stained after permeabilising the cells with 0.2% TX-PBS for
10 min subsequent to fixing of the cells with 4% PFA solution for 10 min. Cells were then
incubated with primary antibodies diluted in 3% BSA/0.2%TX-PBS solution for one hour
at room temperature:
-

Anti-Vimentin antibody conjugated to Alexa Fluor® 647 dye (VIM-647; clone V9,
Abcam) was tested using dilutions of 1/1000, 1/2000, and 1/5000.

-

Anti-ABCB5 mouse antibody (clone 5H3C6, Abcam) was tested using 1/20, 1/50,
and 1/100 dilutions.

For the ABCB5 marker, melanoma cells were washed 3 times with 0.2%TX-PBS and
incubated with a donkey anti-mouse IgG polyclonal antibody conjugated to Alexa Fluor®
488 dye (M488; Abcam) diluted 1/500 in 3% BSA/0.2%TX-PBS and kept for 15 min at
room temperature in the dark (See Table 7).
Lastly, after the melanoma cells were stained for either cell surface or intracellular
markers and secondary antibodies, cells were mounted with Prolong® Gold antifade
reagent with DAPI mounting media (Thermo Fisher Scientific, USA) for nuclear staining
and preservation of the cells. The slides were kept at 4 C until their analysis was
performed.
Slides stained with RANK and ABCB5 were scanned using a fluorescence microscope
(BX51, OLYMPUS, Japan) with a FITC and DAPI filter. Negative controls that involve
incubating the sample with secondary antibodies only were performed for each marker
and in each cell line in order to detect the background level of expression. The expression
analysis was performed using the DPController software, version 3.3.1.292 and
background subtraction was performed for each marker and cell line by adjusting the
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intensities and exposures as per matched negative controls. On the other hand, slides
stained with Vimentin were scanned using an automated inverted fluorescent
microscope (Eclipse Ti-E, Nikon®, Japan; Figure 18), and analysed.
Negative controls that involve incubating the sample with an isotype matched antibody
labelled with Alexa Fluor® 647 dye at the same concentration as the Vimentin antibody
were performed for each cell line in order to detect any background non-specific signal.
Background subtraction was performed for each cell line and marker Using the NISElements High Content Analysis software, version 4.2 using the Cy5 filter to identify the
marker staining and the DAPI filter for nuclear recognition, background subtraction
parameters were adjusted for each marker by altering the fluorescent intensity cut-offs
(LUTs) as per matched negative controls. After background subtraction, signal for each
fluorescent dye was also adjusted to enhance the staining for each marker.
Table 7. Antibody information (Aim 3).
Antibody

Antigen
Location

Vendor

RANK

Membrane

R&D Systems
Clone 80704

Vimentin-AF647

Cytosol

Abcam
Clone V9

ABCB5

Internal
Membrane

Abcam
Clone 5H3C6

ABCB5

External
Membrane

1D12
n/a (donated)

MCSP

Membrane

CD45-PE

Membrane

Donkey antimouse-AF488

n/a

BD Pharmingen™
554275
BD Pharmingen™
Clone HI30
Abcam
Ab150109

Dilutions
tested
1/20
1/50
1/100
1/1000
1/2000
1/5000
1/20
1/50
1/100
1/550
1/275
1/100

Dilution
used

Notes

1/20

Additional Ab tested

1/1000

Additional Ab tested

1/20

Additional Ab tested

1/275

Tested for TSA

n/a

1/500

Positive control for TSA

n/a

1/20

n/a

1/500

Leukocyte-specific
antibody
Secondary Polyclonal
Ab

TSA: Tyramide Signal Amplification

Optimised immunofluorescent staining of A2058 melanoma cells spiked into WBCs
The specificity of the selected markers was next assessed by determining their expression
patterns when A2058 melanoma cell line cells were spiked into WBCs isolated from the
blood of healthy donors. This was required to ensure that the WBCs did not express the
melanoma markers and to ensure that the staining remained optimal when melanoma
cells were spiked into WBCs.
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For this, melanoma cells of the A2058 cell line were spiked into WBCs from healthy
volunteers. Spiking and whole blood RBCs lysis were performed as previously described
in section 4.1.1. Approximately 5x103 A2058 melanoma cells and 105 WBCs were mixed,
pelleted and fixed by resuspending them in 2% PFA for 10 min. Then, cells were
transferred onto glass slides using the Cytospin 4® centrifuge (Thermo Fisher Scientific,
USA; Figure 17) for 5 min, at 2000 rpm with medium acceleration. Attached cells were
then fixed again with 4% PFA for 10 min and washed twice with PBS in a coupling jar.
After the cells were cytospun and fixed onto glass slides, cells were blocked with a
blocking buffer containing 10% normal donkey serum (NDS), 3% bovine serum albumin
(BSA) diluted in PBS or in 0.2% TX-PBS for internal markers staining. Subsequently, cells
were incubated with different antibodies at their optimal dilutions (Vimentin: 1/1000;
RANK: 1/20 and ABCB5: 1/20), in blocking buffer for one hour at room temperature.
Then, cells were washed 3 times with PBS or 0.2% TX-PBS (for intracellular markers) and
incubated for 15 min at room temperature in the dark with a donkey anti-mouse IgG
polyclonal antibody conjugated to Alexa Fluor® 488 dye (M488; Abcam) diluted 1/500 in
blocking buffer. In addition, a leucocyte marker, anti-CD45 antibody conjugated to
Phycoerythrin (PE) (CD45-PE; clone HI30, BD Pharmingen) was used to specifically stain
the leucocytes at 1/20 dilution. After washing again 3 times with PBS or 0.2% TX-PBS (for
intracellular markers), cells were mounted with Prolong® Gold antifade reagent with
DAPI mounting media (Thermo Fisher Scientific, USA) for nuclear staining and
preservation of the cells.
The slides were kept at 4 C until their analysis was performed. Slides were scanned using
an automated inverted fluorescent microscope (Eclipse Ti-E, Nikon®, Japan). Marker
expression patterns were analysed using the NIS-Elements High Content Analysis
software, version 4.2.
RANK and ABCB5 markers were identified using a FITC filter with set excitation and
emission (Ex/Em) wavelengths of 470/535 nm with an exposure time of 700 ms. The
signal produced by VIM-647 expression was identified using a Cy5 filter (Ex/Em =
640/720 nm) with an exposure time of 1 s. On the other side, CD45-PE stained leukocytes
were identified using a TRITC filter (Ex/Em = 555/607 nm) with an exposure time of 500
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ms. Nuclear staining was identified with a DAPI filter (Ex/Em = 395/460 nm) with an
exposure time of 200 ms.
In order to be counted as appropriately stained, the cell needed to have positive
expression for the nuclear DAPI staining and also be positive for the melanoma marker
tested (Vimentin, RANK or ABCB5), but negative for the CD45 leukocyte-specific marker.
Background subtraction parameters were adjusted for each marker by altering the
fluorescent intensity cut-offs (LUTs). After background subtraction, signal for each
fluorescent dye was also adjusted to enhance the staining for each marker.
Tyramide Signal Amplification (TSA)
In order to further enhance signal of markers that were weakly/intermittently expressed
in melanoma cell lines, such as ABCB5, a tyramide signal amplification (TSA)
methodology was tested (Figure 21).

Figure 21. Tyramide Signal Amplification principle.

Since ABCB5 marker is commonly expressed on CTCs170, and the ABCB5 staining protocol
trialled above produced weak and suboptimal staining, we utilised a Tyramide Siganl
Amplification (TSA) protocol to amplify the immunohistochemical staining signal of
ABCB5. To interrogate, for the first time, the ability of this method to increase the signal
of ABCB5 staining, an anti-ABCB5 antibody that binds to an epitope of the ABCB5 protein
that is located in the external membrane of the cell was used, as this was identified
previously as being commonly expressed on melanoma CTCs170.
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For this, A2058 cells were seeded on sterile square glass cover slips in 12-well cell culture
plates (Greiner Bio-One, Austria) and incubated for 24 hours in DMEM (Invitrogen, USA)
supplemented with 10% foetal bovine serum (FBS) (Invitrogen, USA) and maintained at
37 C in a humidified atmosphere containing 5% (v/v) CO2.
Attached cells were washed with PBS and fixed with 4% paraformaldehyde (PFA) for 10
minutes at room temperature and then washed 3 times with PBS. Cells were then blocked
with a TBS blocking buffer (0.1 M Tris-HCl, 0.15 M NaCl, pH 7.5) supplemented with 3%
BSA at room temperature for 15 min. Anti-ABCB5 mouse antibody (Clone 1D12) was then
incubated for 1 hour at room temperature, diluted 1/275 in blocking buffer and the slides
were washed three times in TBS-Tween washing buffer (0.1 M Tris-HCl, 0.15 M NaCl, pH
7.5, 0.05% Tween-20) for 5 min each under continuous shaking were performed.
Incubation with anti-mouse antibody labelled with horseradish peroxidase (HRP; Perkin
Elmer, USA) diluted 1/1000 in blocking buffer was performed for 30 min at room
temperature. After washing again with washing buffer, the sample was incubated in TSA
Plus Working Solution (Fluorescein; Perkin Elmer, USA) for 5 min. The sample was once
again washed three times for 5 min each in continuous shaking before mounting with
Prolong® Gold antifade reagent with DAPI mounting media (Thermo Fisher Scientific,
USA) for nuclear staining and preservation of the cells. For this experiment, anti-MCSP
antibody diluted 1/500 (BD Pharmingen) was included as a positive control since MCSP
is highly expressed in the A2058 melanoma cell line4. Additionally, a negative control that
involved incubating the sample with the secondary antibody only was performed in order
to detect the background level of expression.
In order to test the specificity of the staining, A2058 melanoma cells were spiked into
WBCs from healthy donors as detailed in section 4.1.1, processed and stained. For this,
cells cytospun onto slides were fixed for 10 min with 4% PFA and washed three times
with PBS. In order to quench the endogenous peroxidase activity of the blood cells, an
incubation in 0.3% H2O2 in PBS for 20 min was performed. After washing again with PBS,
cells were incubated for 1 hour at room temperature with anti-ABCB5 mouse antibody
(Clone 1D12), diluted 1/275 in blocking buffer and washed three times in TBS-Tween
washing buffer (0.1 M Tris-HCl, 0.15 M NaCl, pH 7.5, 0.05% Tween-20) for 5 min each
under continuous shaking. Incubation with anti-mouse antibody labelled with
horseradish peroxidase (HRP; Perkin Elmer, USA) diluted 1/1000 in blocking buffer was
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performed for 30 min at room temperature. After washing again with washing buffer, the
sample was incubated in TSA Plus Working Solution (Fluorescein; Perkin Elmer, USA) for
5 min. The sample was once again washed three times for 5 min each in continuous
shaking before incubating the sample with a leucocyte marker, anti-CD45 antibody
conjugated to Phycoerythrin (PE) (CD45-PE; clone HI30, BD Pharmingen at 1/20
dilution) to specifically stain the leucocytes. After washing again with washing buffer,
cells were mounted with Prolong® Gold antifade reagent with DAPI mounting media
(Thermo Fisher Scientific, USA) for nuclear staining and preservation of the cells.
Additionally, anti-MCSP antibody diluted 1/500 (BD Pharmingen) was included as a
positive control. Additionally, a negative control of mouse IgG1 isotype antibody (clone
MOPC-21; Abcam, USA) alone was used to detect the any background non-specific signal.
Slides were kept at 4 C until their analysis was performed. Slides were scanned using an
automated inverted fluorescent microscope (Eclipse Ti-E, Nikon®, Japan), and analysed
using the NIS-Elements High Content Analysis software, version 4.2 to measure the
marker expression patterns. This software was used to scan across the slide using a FITC
filter with set excitation and emission (Ex/Em) wavelengths of 470/535 nm with an
exposure time of 100 ms or 700 ms to identify ABCB5 and MCSP expression; TRITC filter
(Ex/Em = 555/607 nm) with an exposure time of 500 ms was used for the recognition of
CD45-PE stained leukocytes; and nuclear staining was identified with a DAPI filter
(Ex/Em = 395/460 nm) with an exposure time of 200 ms. In order to subtract the
background expression, fluorescent intensity cut-offs were applied and adjusted for each
marker, matching the negative controls values.
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5. RESULTS
5.1 Aim 1. To measure the efficiency of three spiral microfluidic
approaches to isolate differently sized melanoma cell lines spiked into
healthy control blood.
5.1.1 Recovery rates using microfluidic devices
To assess the capacity of the spiral microfluidic devices to enrich and recover melanoma
cells, 50 x CellTracker labelled cells from two cell lines, with different cell sizes (A2058
and SKMEL5), were spiked into 8 mL of blood donated by healthy volunteers and
processed through 1X Slanted, A5 and 2X Slanted spiral microfluidic approaches.
As observed in Figure 22, the lowest recovery rate for both cell lines was found after
processing the sample through the A5 chip, with an average of 33%. Conversely, the use
of 1X Slanted provided the highest average recovery rate of more than 70% regardless of
the cell size. The 2X Slanted enrichment caused an average recovery rate of 73.3% when
spiking the small A2058 cells, and 56% when the larger SKMEL5 cells were spiked.
Interestingly, the average recovery rates for SKMEL5 cells were lower than for A2058
cells regardless of the enrichment approach used.

Figure 22. Recovery rates from the three enrichment procedures using 50 x spiked cells from
two different cell lines with different cell sizes. Experiments were performed in triplicate using
blood samples from healthy donors (n=3).
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5.1.2 Purity analysis
To evaluate the purity of the enriched fractions, WBCs were counted in the sample prior
to and after processing through the microfluidic chips.
Results showed that by running the sample through the 1X Slanted device, a 2 log
reduction in WBCs was achieved (mean: 9.0 x 104; range: 0.56-1.45 x 105) relative to the
initial WBC count (mean: 1.2 x 107; range: 0.8-1.62 x 107). Similarly, using the A5 device
a 2 log reduction was achieved (mean: 4.3 x 105; range: 2.15-5.45 x 105) relative to the
initial WBC count (mean: 1.6 x 107; range: 1.54-1.80 x 107) (Figure 23).
The need to achieve a higher purity in the enriched fraction, led us to add a second round
of enrichment through the Slanted chip, referred to as double Slanted enrichment (2X
Slanted). This approach offered the highest purity achieving a 3 log reduction in WBC
counts (mean: 1.8 x 104; range: 6750-38250) relative to the initial amount of WBCs
(mean: 1.4 x 107; range: 1.2-1.7 x 107) (Figure 23). Two rounds of enrichment through
the Slanted, showed a significant depletion in WBCs in the enriched fraction (P<0.0001).
In addition, these results show that after 1X Slanted, the recovery of A2058 melanoma
cells drops to 86% and the WBC background results in 73.4% from the total. Although
after 2X Slanted, the recovery of A2058 melanoma cells drops to 73%, the WBC
background represents only 14.7% from the total, confirming the ability of this chip to
reduce the WBC background without drastically impacting the recovery rates. Overall,
the 2X Slanted protocol provided the best balance between recovery and WBC
background reduction needed to implement downstream applications.

Figure 23. WBC counts in the blood of healthy donors (n=3) before and after one or two rounds
of enrichment. Each experiment was performed in triplicate using blood samples from healthy
donors (n=3). 2X Slanted enrichment showed significant depletion in the WBC count (p<0.0001).
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5.2 Aim 2. To detect CTCs from metastatic melanoma patients enriched
by the 2X Slanted device, using an optimised immunostaining protocol.
5.2.1 Cytospin optimisation
In order to confirm that the majority of melanoma cells are transferred onto glass slides
using the cytospin centrifuge, 50 x A2058 cells stained with CellTracker™ and WBCs from
healthy volunteers were cytospun at four different speeds. The majority of spiked cells
were recovered when 2,000 rpm was used. To ensure consistency, this speed was tested
in triplicate, and an average recovery rate of 94% was achieved (Figure 24).

Figure 24. Recovery rates of 50 x A2058 cells labelled with CellTracker after centrifuging them at
different speeds with the Cytospin centrifuge. 2000 rpm speed was tested in triplicate.

Finally, 50 x A2058 cells stained with Celltracker™, were spiked in triplicate into 8 mL of
blood from healthy volunteers, RBCs were lysed, and the sample was processed twice
through the 2X Slanted device prior to cytospinning the sample onto glass slides using a
speed of 2000 rpm. Results showed an average overall (microfluidics plus cytospin)
recovery rate of 58% spiked cells (Figure 25).
5.2.2 Staining optimisation
To ensure that the multimarker immunoassay, previously described in section 4.2.1, is
effective in detecting melanoma cells that have been transferred onto glass slides using
the cytospin centrifuge, 50 x A2058 cells were spiked in approximately 104 WBCs and
cytospun at 2,000 rpm and stained with the multimarker panel in triplicate. Markers
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included MCSP, a melanoma cell surface specific marker, together with a mixture of
internal melanocytic markers, gp100 (glycoprotein 100), Melan-A, and s100 (‘MELstaining’) in order to ensure detection of the majority of melanoma cells. Results showed
an average recovery rate of 92% (Figure 25).
When the same experiment, using 50 x A2058 cells spiked into healthy blood was
performed by conducting the entire process (2X Slanted processing, cytospin and
multimarker immunostaining), the overall average recovery rate was 52% (ranging from
48 to 56%; Figure 25). Thus, the entire process of 2X Slanted resulted in a decrease in the
number of recovered melanoma cells.

Figure 25. Recovery rates of 50 A2058 cells A) Stained with CellTracker® and directly
transferred onto glass slides using Cytospin, B) Stained with Cell Tracker®, spiked into blood,
processed through the 2X Slanted device and transferred onto glass slides using the Cytospin, C)
Directly transferred onto glass slides using Cytospin and stained using the melanoma associated
markers, and D) Spiked into blood, processed using the 2X Slanted device and transferred onto
glass slides using the Cytospin prior to staining with the melanoma associated markers.

Interestingly, although the A2058 spiked cells are thought to be identical as they arise
from a cell line, they showed different patterns of staining (Figure 26) in multiple
experiments, with some cells being stained for only the internal set of markers (Figure
26, CELL 1), other cells for only the MCSP surface marker (Figure 26, CELL 2) and some
cells were stained for both internal and surface markers (Figure 26, CELL 3).
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Figure 26. Microscopic images showing the differential expression of intracellular and cell
surface markers in A2058 cells stained after 2X Slanted microfluidic enrichment. The
immunostaining used to detect melanoma cells uses a combination of intracellular markers –
‘MEL staining’- (gp100, MLANA and s100; AF488 -FITC- Shown here as green), and a surface
marker (MCSP; AF467 -Cy5- Shown here as purple). DAPI (UV- Shown here as blue) was used as
a nuclear stain and CD45 (PE-TRITC- Shown here as red) as a leukocyte-specific marker.

Results show that the majority of the detected cells were positive for internal and
external markers (55%), more than a third expressed only the MCSP surface marker
(39%) and only 6% of the detected cells were positive for the internal markers only. This
results showed that combining numerous markers in the detection of these
heterogeneous cells increases our ability to detect them. The use of different emission
wavelengths to identify the different markers, with the internal markers (FITC) and cell
surface markers (Alexa Fluor® 647) allowed the detection of this marker diversity.
5.2.3 CTCs isolated from the blood of melanoma patients
The above results showed the ability of the multimarker panel used in immunostaining
to successfully detect melanoma cells that have been enriched with the 2X Slanted
microfluidic device. In order to validate this enrichment (Aim 1) and detection procedure,
blood samples from 10 metastatic melanoma patients were analysed. A total of 8 mL of
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blood was treated with lysis buffer in order to deplete red blood cells. Then, the sample
was processed through the Slanted microfluidic device using the 2X Slanted approach,
the recovered cell fraction was cytospun and then immunostained with the multimarker
panel described above.
True CTCs were identified by positive staining for intracellular markers (‘MEL staining’)
or cell membrane MCSP as well as negative staining for the leukocyte-specific marker
CD45 (Figure 27).
Using these enrichment and detection procedures, CTCs were effectively detected in the
blood of 4 patients (40%). Two patients had 1 CTC (CELL 1 and 2), one patient had 3 CTCs
(CELL 3-5) and the other was found with 4 CTCs (CELL 6-9) in 8 mL of blood (Figure 27).
Interestingly, all detected CTCs were positive only for the combination of intracellular
markers (‘MEL staining’ -gp100, Melan-A, and s100-) and no CTC expressing the cell
membrane marker MCSP was found in any of these patients. Size analyses confirmed that
CTCs were larger than the majority of white blood cells, exhibiting an average cell size of
19 µm (range: 13–24 µm), while WBC cell sizes were on average 10 µm (range: 8–12 µm).
All detected CTCs were presented as single cells and no clusters of CTC cells were
detected (Figure 27).
In addition, blood samples from three healthy controls were processed using the same
protocol. The immunostaining of these samples showed that no CTCs were detected in
the healthy control blood samples analysed.
5.2.4 Purity analysis of metastatic melanoma patients samples
To assess the purity of the enriched fractions when isolating cells from patients, WBC
counts were completed before and after processing 8 mL of blood from five metastatic
melanoma patients once and twice through the Slanted microfluidic device. As illustrated
in Figure 28, a 2-3 log reduction in WBCs compared to the initial WBC count of 3.5 x 107
(range: 2.36 x 107 - 4.94 x 107) was achieved, after the first round of Slanted, 7.7 x 105
WBCs (range: 2.45 x 105 - 4.65 x 105) and after 2X Slanted, 8.7 x 104 WBCs (range: 46,532
– 123,203). A second round of enrichment significantly depleted the WBCs (p<0.0001) in
patient samples even though the initial amount of WBCs was higher in patients than in
healthy controls.
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Figure 27. Expression pattern of intracellular and cell surface markers in CTCs isolated from
metastatic melanoma patients. The immunostaining used a combination of intracellular markers
-‘MEL staining’- (gp100, MLANA and s100; AF488 -FITC- Shown here as green), and a surface
marker (MCSP; AF647 -Cy5- Shown here as purple). DAPI (UV- Shown here as blue) was used as
a nuclear stain and CD45 (PE -TRITC- Shown here as red) as a leukocyte-specific marker.
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Figure 28. WBCs counts in five patients prior to and after 1 and 2 rounds through the Slanted
microfluidic device. A second round of enrichment showed significant depletion of WBCs
(p<0.0001).

5.3 Aim 3. To test additional cellular markers that can be used in
immunostaining assays for optimisation of detection and phenotypic
characterisation of heterogeneous melanoma CTCs.
5.3.1 Optimisation of immunostaining assays
The low number of CTCs identified in patients with active metastatic disease, revealed
the urgent need to test additional markers that can be used for detection of CTCs in
samples processed through the Slanted microfluidic device. This is supported by previous
observations that melanoma CTCs are heterogeneous and most commonly express
cancer stem cells markers (ABCB5 and RANK) in addition to melanoma specific markers
(gp100, Melan-A s100, and MCSP)4, 170, 174. Thus, it is possible that these stem cell-like
melanoma CTCs were not detected in the patient samples isolated above, because these
stem-like CTCs may not express the melanocytic markers included in our panel.
Therefore, in this project, we established staining protocols for an additional 3 markers
associated with cancer stem cell features: Vimentin213, RANK215, and ABCB5222. These
markers have been detected previously in melanoma CTCs170 and therefore their
inclusion in this study could potentially improve melanoma CTC detection rates.

64

5. RESULTS

Firstly, the optimal dilutions of the antibodies used for their detection was determined
by studying the immunocytochemical staining at different dilutions. Secondly, their
expression in three melanoma cell lines (A2058, WM164, and SKMEL5) was analysed.
Overall, the optimal immunostaining protocol for detection of expression of these
markers in melanoma cells and the optimal antibody dilution was determined (see Table
7). Results from these experiments will inform future studies of the expression of these
stem-like markers in CTCs from melanoma patients.
Each antibody was tested using three different dilutions as per the manufacturer´s
recommendations. The optimal concentration of each antibody was assessed by
determining the concentration that provided optimal immunocytochemical staining in
melanoma cells whilst showing minimal background/ non-specific staining.

Figure 29. Antibody dilution optimisation. A2058 cells stained with different dilutions of
Vimentin (AF647 -Cy5- Shown here as purple), RANK and ABCB5 (AF488 -FITC- Shown here as
green). DAPI for nuclear recognition (UV- Shown here as blue). Negative controls were assessed
for each marker (M488 for ABCB5 and RANK, and -647 ISO for Vimentin). Images at 40x
magnification. Scale bar denotes 100 µm.
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As shown in Figure 29, using an optimal concentration of 1/1000, anti-vimentin antibody
stained the highest number of melanoma cells. A dilution of 1/20 for the anti-RANK
antibody stained cells with minimal non-specific staining. Similarly, a dilution of 1/20 for
the anti-ABCB5 antibody showed weak staining in a large number of cells.
5.3.2 Analysis of stem cell marker expression in melanoma cell lines
The optimal dilutions determined above for each marker were used to stain two
additional melanoma cell lines: WM164, and SKMEL5 and the results were compared to
those received for A2058 stained cells.
Table 8. Expression analysis of Vimentin, RANK and ABCB5 markers across three
melanoma cell lines.

Proportion of cells with positive staining (%)
Marker
Vimentin

RANK

ABCB5

`

A2058

WM164

SKMEL5

Level of expression*

0-20

40-60

0-20

High

20-40

20-40

20-40

Moderate

20-40

0-20

20-40

Low

0
0-20
20-40

0
0-20
0-20

0
0
20-40

*Exemplified in Figure 29

0

0

0

0

0

0

40-60

0-20

0-20

Figure 30. Differential staining to exemplify the level of expression of Vimentin, RANK, and
ABCB5 across three melanoma cell lines. 1. Low level of expression. 2. Moderate level of
expression. 3. High level of expression. Scale bar denotes 40 µm.
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The expression analysis revealed high Vimentin expression, predominantly by WM164
cells (60%). However, some A2058 and SKMEL5 cells also had also high Vimentin staining
intensities. In addition, a greater proportion of cells expressed moderate Vimentin
staining across all cell lines, with SKMEL5 and A2058 being the cell lines with more cells
presenting low staining intensities (Table 8; Figure 31).
RANK was mainly expressed by the A2058 cell line at moderate to low levels of
expression. WM164 also expressed this marker in less than half of the cells at moderate
to low levels of expression. On the other hand, SKMEL5 showed low levels of RANK
expression in approximately half of the cells (Table 8; Figure 31).
ABCB5 was the marker with the lowest expression across all cell lines. Low levels of
expression were mainly observed in the majority of the A2058 cells. The other two cell
lines, WM164 and SKMEL5 expressed this marker at low levels in only some cells and no
positive staining for ABCB5 was present in most of the cells (Table 8; Figure 31).
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Figure 31. Expression pattern of the three additional markers across three melanoma cell lines
(A2058, WM164 and SKMEL5). Intracellular markers Vimentin (AF647 -Cy5- Shown here as
purple) and ABCB5 (AF488 -FITC- Shown here as green), and cell surface marker RANK (AF488 FITC- Shown here as green). DAPI was used as a nuclear stain (UV- Shown here as blue). Negative
controls were assessed for each marker in each cell line (647 ISO for Vimentin, and M488 for
ABCB5 and RANK). Images at 40x magnification. Scale bar denotes 100 µm.
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5.3.3 Analysis of the specificity
To determine the specificity of the markers in staining melanoma cells and not WBCs,
A2058 cells were spiked into WBCs and transferred onto glass slides using the Cytospin
then stained for each marker. In addition, negative control experiments were performed
for each marker.
Vimentin
Vimentin showed different patterns of staining in spiked cells (Figure 32). Around 60%
of cells had low expression of this marker and were slightly stained (i.e. Figure 32, CELL
1), whereas 30% of cells expressed higher amounts of Vimentin (i.e. Figure 32, CELL 2)
and 10% cells were completely negative for this marker (i.e. Figure 32, CELL 3).
Importantly, no WBCs were positively stained for Vimentin, showing the specificity of this
marker in detecting melanoma cells.

Figure 32. Microscopic images indicating the differential Vimentin expression intensities
observed for A2058 melanoma cells spiked into WBCs. The immunostaining shows vimentin
expression (AF647 -Cy5- Shown here as purple). DAPI (UV- Shown here as blue) was used as a
nuclear stain and CD45 (PE -TRITC- Shown here as red) as a leukocyte-specific marker. Scale bar
denotes 15 µm.
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RANK
As observed in Figure 33, spiked A2058 cells did not express RANK over the background
level. In addition, some WBCs showed positive signal for the marker. This findings are
supported by the literature describing the expression of RANK in WBCs215, 223.

Figure 33. Microscopic images showing the RANK staining pattern in spiking experiments. The
immunostaining uses an anti-RANK antibody (AF488 -FITC-Showed here as green). DAPI (UVShown here as blue) was used as a nuclear stain and CD45 (PE -TRITC- Shown here as red) as a
leukocyte-specific marker. Scale bar denotes 15 µm.

ABCB5
As presented in Figure 34, ABCB5 staining was highly specific for melanoma cells, with
no WBCs staining positive for this marker (i.e. Figure 34, WBC 1). However, the weak
staining pattern present in A2058 spiked cells showed that this marker is expressed very
weakly in melanoma cells. A few cells (10%) were stained only at the margins of the cell
(i.e. Figure 34, CELL 1) and some cells (30%) were stained in a very speckled pattern,
which makes it difficult to confidently identify them as ABCB5 positive cells (i.e. Figure
34, CELL 2). The majority of cells were negative for ABCB5 expression.
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Figure 34. Microscopic images showing the ABCB5 staining pattern in spiked cells. The
immunostaining uses an anti-ABCB5 antibody (R488 -FITC- Shown here as green). DAPI (UVShown here as blue) was used as a nuclear stain and CD45 (PE -TRITC- Shown here as red) as a
leukocyte-specific marker. Scale bar denotes 15 µm.

5.3.4 Tyramide Signal Amplification in ABCB5 marker.
Tyramide Signal Amplification (TSA) is an enzyme-mediated detection method that
utilises the catalytic activity of horseradish peroxidase (HRP) to generate a high-density
labelled target protein thereby providing an intensified staining signal.
The above results show that A2058 cells express ABCB5 very weakly, complicating the
detection and characterisation of these ABCB5 positive cells. Therefore, the TSA was
trialled in order to discover if this method of immunostaining improves the signal shown
by ABCB5 positive cells, therefore improving their detection.
Firstly, in order to test the ability of this method to increase and amplify the expression
signal, MCSP, a marker known for being expressed by A20584, was tested as a positive
control. When MCSP was tested using the TSA methodology and the same exposure and
fluorescent intensities for both, standard and TSA immunocytochemistry methods, the
level of signal observed for MCSP expression was higher (Figure 35.A2) than that of the
signal obtained by staining with the standard immunocytochemistry protocol (Figure
35.A1).
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Next, the ABCB5 expression was tested in order to verify the ability of this method to
increase the signal produced by A2058 cells that express this marker in low amounts. For
this, we utilised an antibody that recognises an epitope in a domain of ABCB5 that is
situated on the external side of the cell membrane (Clone 1D12)217. Results show that,
compared with the standard immunocytochemistry (ICC) protocol (Figure 35.B1), the
TSA improved the level of intensity of the signal denoting ABCB5 expression (Figure
35.B2), allowing the detection of a higher number of ABCB5 positive cells (60%).

Figure 35. Differential signal shown by A2058 cells when comparing the TSA method with
standard immunocytochemistry. Marker expression of A2058 cells stained with (A1) anti-MCSP
antibodies (anti-mouse-AF488. Shown here as green), (A2) anti-MCSP antibodies (anti-mouseHRP, fluorescein. Shown here as green), and (A3) negative control without primary antibody,
treated with anti-mouse-HRP (fluorescein). (B1) Cells stained with anti-ABCB5 antibodies (antimouse-AF488. Shown here as green), (B2) anti-ABCB5 antibodies (anti-mouse-HRP, fluorescein.
Shown here as green), and (B3) negative control without primary antibody, treated with antimouse-HRP (fluorescein). DAPI was used as a nuclear stain (UV- Shown here as blue). Scale bar
denotes 100 µm.

Before applying this methodology in samples containing spiked A2058 cells and WBCs,
the endogenous peroxidase activity of the WBCs was tested. For this, WBCs only were
stained with isotype antibodies, anti-mouse secondary antibody labelled with HRP and
then with the TSA Working Solution that contains fluorescein. CD45 antibody was used
for leukocyte staining.
In this setting, the fluorescein present in the working solution is normally activated by
the peroxidase activity of the HRP added to the experimental sample. However, in this
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case, the presence of peroxidase activity in the WBCs activated the fluorescein, showing
nonspecific signal in the WBCs (Figure 36.A). This nonspecific fluorescence present in
WBCs is thought to be due to endogenous peroxidase activity present in the
eosinophils224.
In order to block this non-specific background signal and avoid the nonspecific staining,
three different concentrations of a blocking agent, hydrogen peroxide (H2O2) were tested.
Results show that by incubating the cells prior to staining with 0.3% H2O2 in PBS for 20
min, the endogenous peroxidase activity was blocked (Figure 36.B) as the fluorescein
signal was not detected.

Figure 36. Differential expression pattern in WBCs treated or not with hydrogen peroxide. (A)
WBCs stained with a mouse isotype control (negative control) and anti-mouse-HRP showing the
endogenous peroxidase activity (-FITC-Shown here as green). (B) Nonspecific signal quenching
after treating the sample with 0.3% H2O2. DAPI (UV- Shown here as blue) was used for nuclear
staining and CD45 (PE -TRITC- Shown here as red) as a leukocyte-specific marker. Scale bar
denotes 100 µm.

To study the specificity of this methodology for staining melanoma cells, A2058 cells
spiked into WBCs were treated with 0.3% H2O2 peroxidase quenching solution and then
tested for ABCB5 expression. Again, MCSP was used as a positive control, and an isotype
negative control was also used to detect the background level of non-specific staining.
Results showed that the majority of A2058 cells (60%) presented with a higher signal
intensity than that found in previous spiking experiments without TSA amplification
(Figure 34).
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The MCSP staining used as a positive control provided a high signal in all spiked A2058
cells after TSA amplification (Figure 37.B). By contrast, ABCB5 expression was mainly
present on the periphery of the cells (Figure 37.A), with some cells showing low or no
staining. This is as expected since ABCB5, a stem cell marker225, is not expected to be
present in all cells and confirms the specificity of the observed staining. Negative controls
performed with an isotype antibody were used to define the background level of nonspecific staining (Figure 37.C).

Figure 37. Marker expression of A2058 cells spiked in WBCs. Cells stained with (A) anti-ABCB5
antibodies at 20 µg/mL (anti-mouse-HRP, fluorescein -FITC- Shown here as green), (B) Positive
control with anti-MCSP antibodies (anti-mouse-HRP, fluorescein; green), and (C) negative control
with mouse isotype antibodies DAPI (UV- Shown here as blue) was used as a nuclear stain and
CD45 (PE -TRITC- Shown here as red) as a leukocyte-specific marker. Scale bar denotes 50 µm.

In summary, TSA specifically enhanced immunostaining of these two melanoma markers.
Most importantly, the staining signal of the weakly expressed stem cell marker, ABCB5,
was significantly improved by TSA, allowing a more accurate detection of the expression
of this marker in melanoma cells when immunostaining is used for their detection.
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The isolation of CTCs is critical for the understanding of the role of these cells in the
metastatic process and in determining their utility as biomarkers in the clinical
management of cancer. The extreme heterogeneity of melanoma CTCs, also demands the
implementation of better methods for the isolation and identification of the whole
diversity of melanoma CTCs present in the blood of melanoma patients. Therefore, the
application of methods that enable the isolation of viable CTCs and detection methods
that allow the identification of these highly heterogeneous cells, is of high biological and
clinical significance.
This project was aimed at developing an optimal procedure for the isolation and
identification of CTCs in the blood of melanoma patients. The 2X Slanted microfluidic
device was shown here, for the first time, to allow enrichment of CTCs from the blood of
metastatic melanoma patients. This is of importance since only two microfluidic devices
(CTC-iChip and Cluster-Chip) have been utilised previously for the isolation of CTCs from
melanoma patients178, 185. The protocols required to successfully transfer the microfluidic
enriched CTCs onto coverslips using the cytospin, and to detect the CTCs by
immunofluorescence, were also developed. Here the detection of CTCs was achieved
using a multimarker panel that combines four cellular markers involved in melanocytic
function and melanomagenesis, commonly used in melanoma diagnosis. Since melanoma
is a very heterogeneous cancer and melanoma CTCs have been shown to express different
markers, the expression of three additional markers that can potentially improve the
possibility of capturing heterogeneous CTCs, was evaluated in melanoma cell lines.

6.1 Microfluidic devices in melanoma CTC enrichment
Several methods have been developed to isolate melanoma CTCs from blood samples,
predominantly using cell surface markers to capture and isolate the CTCs. However, due
to the extraordinary marker heterogeneity found in melanoma, these methods bias the
isolation to include only a proportion of CTCs. Thus, methods such as those based on the
use of microfluidic devices, which isolate CTCs based on their physical properties relative
to the other blood components, rather than surface marker expression, would improve
CTC isolation and are thus of significant benefit in melanoma CTC research.
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Recovery rates
The study and comparison of the recovery rates and the purity obtained by using
different spiral microfluidic approaches, determined that the best recovery rate was
offered by the 1X Slanted chip, which retrieves more than 80% of spiked melanoma cells.
A similar result has been reported previously by Warkiani et al. for spiked breast and
bladder cancer cell lines, where a recovery rate of ~85% was achieved11. By contrast, the
A5 device, failed to capture more than half of the spiked melanoma cells, in contrast to
previous reported results of >85% of recovery of breast cancer cells (MCF-7)12.
Surprisingly, the SKMEL5 cells, previously characterised as larger than A2058 cells226,
showed a lower recovery rate when spiked and processed through the different spiral
devices. This difference was amplified by the use of the A5 device that recovered, in the
enriched fraction, only 10.6% of the 50 spiked SKMEL5 compared with 55.3% recovery
observed when A2058 cells were spiked. It is possible that the A2058 and SKMEL5 cells
may not only differ in size but also in other physical properties such as cell density or
deformability, affecting their differential recoveries. Remarkably, previous experiments
using the multiplexed version of the A5 chip199, also showed a lower recovery rate
(76.4%) when larger cell line (T24; ~30 µm) rather than a smaller cell line (MCF-7; ~20
µm) was used (87.6%).
Additionally, the recovery rates of melanoma cell lines using the A5 microfluidic device
have not been reported previously. A2058 and SKMEL5 melanoma cell lines have a
smaller average cell size (13.7 µm and 18.2 µm, respectively226) than the breast cancer
cells used in A5 studies12. Taken together, the results support the idea that tumour cells
from the same cancer type may have differential characteristics that may affect their
recovery rates by microfluidics. Therefore, the use of multiple cancer cell lines is
recommended when testing the recovery rates of microfluidic enrichment devices for
CTC isolation.
Purity
Although melanoma CTCs have been detected and quantified previously by using labeldependent methodologies4, 165, 168, 169, one of the most important advantages of using
label-free isolation methods is the ability to enrich a viable and intact CTC population.
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This method of isolation allows CTC downstream analyses of CTCs aimed at unveiling the
genomic and transcriptomic profile of CTCs. Towards this end, achieving a highly purified
enriched fraction is of vital importance for any type of downstream genomic analysis.
Given that the purity of the recovered fraction is a high priority for future applications,
interrogation of the WBC background resulting from these different approaches was
important and here it is shown for the first time that the enrichment through the A5 chip
resulted in the highest WBC background when melanoma cells are isolated. Therefore, no
further experiments were conducted using this spiral device. Although the 1X Slanted
resulted in a more than 2 log fold reduction of WBC background from the blood of healthy
donors and patients, this chip showed a higher leukocytic background than previously
reported of 5 x 103 WBCs per 8 mL11. For this reason, the ability of the 2X Slanted to
further deplete the WBC background while still providing significant recovery rates, was
interrogated. The 2X Slanted spiral microfluidic device achieved close to a 3 log reduction
of WBCs after a second round of Slanted enrichment without markedly affecting the
enrichment efficiency (>60%).
However, despite the need to further improve the leukocytic background yielded by the
slanted device in controls (18,000 WBCs per 8 mL of blood), these values are better than
those reported for the only other microfluidic device used for melanoma CTCs, the CTCiChip (32,000 WBCs per mL of control blood), which was previously used for isolation of
melanoma CTCs185.
Further strategies testing the application of additional WBC depletion methodologies to
blood prior to enrichment through the 2X Slanted enrichment, such Ficoll density
centrifugation, or negative leukocyte depletion of the enriched fraction after 2X
Slanted227, are strongly recommended. However, the potential of the Ficoll density
centrifugation to deplete WBCs prior to microfluidic enrichment needs to be tested since
these methods could affect physical properties of the cells and therefore affect the
recovery rates. Another technique that can be used to obtain pure CTCs for downstream
applications such as single cell sequencing are laser capture microdissection of the cells
on the stained slide or picking of the cells after the staining. Although these processes
may increase the purity of the enriched cells, is important to consider that the addition of
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extra manipulation steps to the enrichment process, may increase cell damage and cell
loss.
Ultimately, the combination of the purity and recovery rate of the 2X Slanted offered the
best outcome amongst the three different spiral microfluidic approaches tested.
Therefore, this approach was validated for the enrichment of CTCs from the blood of
metastatic melanoma patients.

6.2 Detecting CTCs in metastatic melanoma patients
Detection and quantification of CTCs after enrichment through label-free approaches,
such as microfluidic devices, is critical for the validation of these isolation techniques.
In this project, four melanocytic markers (gp100, Melan-A, s100 and MCSP), have been
used to detect CTCs at a single cell level in the background of thousands of WBCs after
microfluidic enrichment of patients’ samples226. These markers have been reported to be
over-expressed in melanoma tumours210, a fact that has driven the extensive use of these
markers in the capture and detection of CTCs from melanoma patients165, 174, 203, 218, 228.
Previous studies have detected melanoma CTCs in 40%168, 57%174, 52%170, 79%165, using
CellSearch®, ISET platform, multimarker flow cytometry and the herringbone CTC-Chip,
respectively. By using the 2X Slanted microfluidic enrichment method and a multimarker
panel for immunostaining detection, CTCs were detected in 40% of the metastatic
melanoma patients analysed. This finding validated, for the first time, the use of the 2X
Slanted microfluidic device in enriching CTCs from the blood of metastatic melanoma
patients. However, it is likely that differences in the CTC detection rates across all CTC
studies may be attributed to the extraordinary heterogeneity of melanoma CTCs both
within and between patients. Therefore, the ability of label-free methodologies, such as
the proposed microfluidic approach, to capture a wider population of viable and intact
CTCs may be beneficial for studies aiming at studying and characterising CTCs using
phenotypic and single-cell genomic approaches, providing a significant advantage over
label-dependant methods which do not allow downstream characterisation of detected
CTCs.
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Although MCSP is highly expressed in both primary and metastatic lesions229, and
different methods have detected MCSP positive CTCs4, 98, the immunostaining approach
used in this project did not detect MCSP positive CTCs in metastatic melanoma patients
enriched using the 2X Slanted device. Ozkumur et al. have indicated a variability of
melanoma CTCs in cell size after microfluidic isolation185, but it is still unclear whether
CTC subtypes do in fact vary in cell size and density. In addition, previous reports
suggested that the population of CTCs expressing melanocytic markers is lower than the
subpopulation of CTCs expressing cancer stem cell markers170.
Based on previous studies4, 170, 174, we expect that not all melanoma CTCs express the
same markers. Therefore, it is possible that the current markers used in downstream
approaches for CTC detection may constrain our ability to detect the vast majority of
melanoma CTC subtypes. Thus, studies aimed at the detection and study of the whole
range of melanoma CTCs to identify the real diversity of these cells are urgently needed
in order to pinpoint better markers that minimise false negative results.
Methods utilised to detect CTCs to date, are derived from our limited available knowledge
of the whole spectrum of the diversity of melanoma CTCs. Studies are needed therefore
to investigate melanoma CTC phenotypes and their role in melanoma biology and
prognosis. Gray et al. found that the proportion of CTCs expressing RANK were
significantly increased after therapy initiation compared with baseline (p=0.0039) in
patients treated with BRAF inhibitors (n=16)170. Similarly, CTCs expressing PD-L1 were
found to be specific biomarkers of response to anti-PD1 blockade171. Thus, prognostic
utility was found not by using total CTCs counts but by studying subpopulations.
Additionally, the pharmacodynamics responses of the different subpopulations of CTCs
to therapy require additional studies to more clearly define the differential relationship
of these subpopulations with response to drugs170.
Importantly, the study of different marker subpopulations is of crucial importance in
melanoma in order to improve our understanding of the role of CTC subpopulations in
melanoma biology. Previous studies comparing melanoma cell subpopulations between
patient-matched blood and metastatic tumours, revealed that cell populations expressing
melanoma initiating markers, such as ABCB5 and RANK, are more common amongst CTCs
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than in the matching tumour, suggesting a preferential selection for certain tumour cell
subtypes in the blood170.
In addition, examining CTC subpopulations and their markers will reveal whether specific
subsets of CTCs are responsible for metastatic initiation and development, thus aiding in
a better classification of high-risk patients or patients in need for adjuvant therapies. In
addition, another important clinical question that could be addressed by characterisation
of CTC subtypes is the identification of differential response or resistance to metastatic
melanoma treatments, providing important information that will impact drug design and
personalised treatment regimes. Such studies will dramatically advance the use of CTCs
in the clinic. Moreover, optimal isolation of melanoma CTCs paves the way for dissection
of their real heterogeneity and the mechanisms underlying their role in melanoma
spreading.

6.3 Additional markers to detect melanoma CTCs
Even though great advances have been made in melanoma CTC isolation techniques,
quantification of melanoma CTCs remains challenging given the low numbers of CTCs
identified even when multimarker assays are used to detect these cells. This exemplified
by our results and by other studies165. The high heterogeneity present in melanoma CTCs
and the low rate of detection of these cells, has highlighted the need to increase the
marker spectrum applied in detecting CTCs.
The immunocytochemistry staining protocol used in patients, identified CTCs expressing
melanocytic markers in 40% of metastatic melanoma patients. However, this method
would miss cells expressing melanoma-initiating markers, which have been shown to be
expressed in a great proportion of CTCs170, 215. Here we optimised immunostaining of
potential markers expressed in melanoma CTCs, including stem-like CTCs in order to
increase CTC detection rates.
Vimentin
Vimentin is an intermediate filaments (IFs) found in the cytoplasm of mesenchymal cells,
maintaining the structure of the cell and the integrity of the tissue230. The presence of
Vimentin in melanoma has been defined as a melanoma diagnostic marker213. The
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detection of this marker in primary tumours has been associated with metastatic
progression, and therefore with worse outcome212, 231, 232.
This study tested the expression of Vimentin in 3 melanoma cell lines. Interestingly, this
marker was expressed by all three cell lines at moderately to high levels. Importantly,
WBCs do not express this marker, as observed in our spiking experiments. Therefore, this
marker is now ready to be used together with the multimarker panel in detecting
melanoma CTCs, Given its high expression in the melanoma cell lines used, it has the
potential to improve the detection of melanoma CTCs.
It has been reported previously that only a proportion of CTCs present in the bloodstream
will ultimately initiate development of a metastatic tumour9. Further studies are needed
to determine whether Vimentin is a marker of aggressive features in CTCs, which can aid
in stratifying patients that require more aggressive treatment.
RANK
Recently, a flow-cytometry multimarker approach was developed, to detect and analyse
CTCs for the presence of melanoma-associated markers, such as MCSP and MCAM, in
combination with melanoma stem cell markers, such as RANK (receptor activator of NFκβ), ABCB5 and CD271170. The evidence provided by Gray et al. that the vast majority of
melanoma CTCs express “stem cell" markers RANK and ABCB5, argues for inclusion of
such markers in CTC detection by immunocytochemistry.
In melanoma, RANK has been described as a tumour-initiating cell marker215. In addition,
Gray et al. found significant association between high numbers of CTCs expressing RANK
and shorter PFS rates in patients treated with MAPK inhibitors. Therefore, the study of
this marker expression in melanoma CTCs serves as a prognostic marker for patients
treated with MAPK inhibitors.
When studying RANK expression across three melanoma cell lines, cells expressing RANK
were observed at moderate to low levels. However, when A2058 cells spiked into WBCs
were assessed, no spiked cells were found positive for RANK. One possible explanation
for this loss of signal in spiked cells, can be the fact that attached cells express RANK on
their cell surface. In contrast, spiked cells that have been subjected to important changes
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in their conditions during spiking, may internalise RANK. In fact, differential staining was
observed between cells grown on coverslips and those spiked into WBCs for all markers
tested, supporting the hypothesis that cells stained in spikes suffer loss of cell surface
markers.
ABCB5
The expression of ABCB5, a tumour initiating or ‘stem cell’ marker known to be involved
in tumour resistance to therapy, was tested in melanoma cell lines and in spiked cells.
ABCB5 identifies a subset of slow-cycling tumour cells with increased potential to initiate
metastases217, 233.
The identification of this marker in melanoma CTCs is of great clinical significance, as it
is present in increased proportion of CTCs in patients resistant to targeted therapies233.
Thus, the presence of ABCB5 positive CTCs, may serve as a predictor of poor responses
to the targeted therapy. Using the staining protocol developed here, we now could
explore this important question in future studies.
The study of ABCB5 expression in spiked cells, did not allow confident recognition of
ABCB5 positive cells. The staining of this marker showed low expression signal in all
three melanoma cell lines even when stained on coverslips. The TSA system is reported
to increase the detection of poorly expressed proteins by 100-fold234. By applying this
methodology to the ABCB5 staining, an increased signal was observed compared with
standard immunocytochemistry. Now, the ability to detect ABCB5 in the microfluidic
enriched fraction of metastatic melanoma patients needs to be tested.
In summary, while previous studies have been able to identify CTCs by using flow
cytometry, there is an increasing need to unveil the genomic, transcriptomic and
proteomic signature of CTCs. In order to perform such analyses, label-free approaches,
such as microfluidics devices, are required. In future studies, microfluidic technology will
dramatically assist with single-cell genomic downstream analyses. Although this
methodology requires a high level of optimisation, the addition of multiple markers
including rare CTC markers, can be a beneficial step towards unveiling the real
heterogeneity of melanoma CTC subpopulations.
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6.4 Limitations of the study
Our study of the isolation of melanoma CTCs has several limitations. One such limitation
is that there is no knowledge of the ability to detect CTCs in patients with low disease
burden, even those with metastatic disease, especially when only 8 mL of blood are
analysed. The analysis of larger amounts of blood would increase the chances of detecting
CTCs, however, this is not feasible in a clinical setting where patients are required to
provide several blood samples for other clinical measures. Another limitation is that cell
lines used here for optimisation of protocols are unlikely to have the same characteristics
as CTCs. Despite melanoma cell lines being critically useful in understanding melanoma
biology, the culture conditions of these cell lines might cause some changes to cell
morphology, biology, and cell surface markers, in particular, when compared to CTCs
derived from melanoma tumours. Thus, it is possible that cell line cultures derived from
melanoma tumours may differ in shape or size from the CTCs present in patients. Changes
in cell size or shape of melanoma CTCs and melanoma cell line cells may induce a different
interaction with the Dean forces generated inside the micro-channels of these biochips.
Consequently, changes in the recovery rates of melanoma cell lines compared to CTCs
derived from patients are likely.
An additional limitation is the high marker heterogeneity present in CTC populations.
Although in this project different markers have been utilised to improve the detection of
CTCs by immunostaining approaches, cell culture conditions may alter the expression of
certain markers and cell lines may not express the same markers or the same level of
markers as those found in CTCs.
On the other hand, the method of enrichment and detection had several steps that could
have affected the integrity of the cells, interfering with marker expression or cell
integrity. Also, the processing timeframe of 24 hours could be too long and cause damage
to the cells, hampering their isolation. To confirm this, studies that investigate marker
expression on CTCs at several steps along the pathway and processing samples within 4
hours of collection need to be performed.
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6.5 Future directions
Challenges in the isolation and detection of CTCs, particularly in melanoma, have
hindered studies aimed at unveiling the molecular mechanisms underlying melanoma
CTC biology and metastasis.
Moreover, use of the 2X Slanted microfluidic device to isolate viable and label-free
melanoma CTCs, will pave the way for studies aimed at dissecting their real heterogeneity
and subsequently the mechanisms underlying their role in melanoma metastasis.
Although challenging, studying the marker expression, gene expression and mutational
landscape of single melanoma CTCs, their relationship with tumour tissue cells and their
connection with treatment response and resistance will significantly increase the clinical
value of CTCs as a biomarker and dramatically advance CTC use in the clinic.

6.6 Conclusion
This project developed and validated the use of a double round of enrichment using the
Slanted microfluidic device in capturing CTCs from the blood of metastatic melanoma
patients. A multimarker assay including four common melanoma markers was used in
order to detect CTCs present in the enriched fraction. This method of enrichment and
detection identified CTCs in 40 % of the ten metastatic melanoma patients examined.
Two additional stem cell markers, Vimentin, and ABCB5, have been identified as potential
markers that can be used in detecting a higher number of melanoma CTCs after spiral
microfluidic enrichment. The use of TSA in detecting markers that are not highly
expressed in CTCs but are of great importance in melanoma management will facilitate
the detection of a broader spectrum of heterogeneous CTCs.
Ultimately, the isolation of viable, label-free heterogeneous populations of melanoma
CTCs using this slanted enrichment device will facilitate future studies aimed at unveiling
the molecular mechanisms and biology of melanoma CTCs and their role in melanoma
metastasis and response to therapy.
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8. APPENDICES
8.1 Supplementary Tables and Figures
Table S1. Important genes in melanomagenesis2.

*Abbreviated forms of the gene are given in parentheses.
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Figure S1. Major pathways involved in melanoma. Pathways associated with cell proliferation,
survival, and differentiations are schematically presented. Arrows, activating signals; interrupted
lines, inhibiting signals. AMPK, AMP-activated protein kinase; Aurk, Aurora kinase; BAD, BCL-2
antagonist of cell death; CDK4, cyclin-dependent kinase 4; CDKN2A, cyclin-dependent kinase
inhibitor of kinase 2A; ERK, extracellular-related kinase; HGF, hepatocyte growth factor; MITF,
microphthalmia-associated transcription factor; MEK, mitogen-activated protein kinaseextracellular-related kinase; PI3K, phosphatidylinositol 3 kinase; PTEN, phosphatase and tensin
homolog; RB, retinoblastoma protein; TERT, telomerase reverse transcriptase235.
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